Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
4/24/2017New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options CINCINNATI, April 24, 2017 (GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation. Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based... 
 Printer Friendly Version
4/17/2017ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) will feature impressive results regarding a revolutionary breakthrough in the world of malaria detection. His presentation at ECCMID is scheduled for April 25, 2017, which is also World Malaria Day. Dr. ... 
 Printer Friendly Version
3/29/2017Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017
CINCINNATI, March 29, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2017 operating results before the NASDAQ market opens on Thursday, April 27, 2017. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, mark... 
 Printer Friendly Version
3/27/2017Bioline Launches New JetSeq DNA Quantification Kits
CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation. The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Libr... 
 Printer Friendly Version
3/7/2017Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa
CINCINNATI, March 07, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian since March 2016, has signed an exclusive distribution agreement with Biofirm Technologies, one of the leading providers of laboratory equipment, consumables, reagents, and medical equipment in East and Central Africa. Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capa... 
 Printer Friendly Version
2/8/2017Bioline Launches New JetSeq™ DNA Library Preparation Kits
CINCINNATI, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the JetSeq™ DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation. Developed in collaboration with Oxford Gene Technology (OGT), the new JetSeq™ DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the pr... 
 Printer Friendly Version
2/3/2017Meridian Bioscience Announces the Launch of TruQuick™ Rapid Tests for Asia Pacific
CINCINNATI, Feb. 03, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TruQuick™, a comprehensive point-of-care product menu of rapid tests for the diagnosis of tropical, infectious, sexually transmitted, respiratory, gastrointestinal, cancer, and cardiac diseases. This product menu will enable Meridian to rapidly expand its product portfolio of high value rapid tests for its commercial operations in Asia Pacific and other emerging markets around th... 
 Printer Friendly Version
1/25/2017Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward
GENERAL HIGHLIGHTS CINCINNATI, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported first quarter net revenues of $46.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $10.1 million, a decrease of 26% from the same period of the prior fiscal year; reported first quarter net earnings of $6.3 million, or $0.15 per diluted share, decreases of 29% compared to the fiscal 20... 
 Printer Friendly Version
1/12/2017Microbix Appoints Meridian Life Science as Distributor in Asia Pacific
Meridian an Exclusive Distributor in China, Hong Kong, Taiwan and Macau TORONTO, ONTARIO--(Marketwired - Jan. 12, 2017) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix"), an innovator of biological products and technologies, today announced it has signed a distribution agreement (the "Agreement") with Meridian Life Science, Inc. ("Meridian") a wholly owned company of Meridian Bioscience, Inc. (NASDAQ:VIVO) a fully integrated global diagnostic and life science company. Under the terms of the Ag... 
 Printer Friendly Version
1/9/2017Bioline Launches the Full Range of EPIK™ miRNA Assays
CINCINNATI, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,00... 
 Printer Friendly Version
12/20/2016Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Signs Exclusive Partnership to Expand Blood Lead Testing in China
CINCINNATI, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Magellan Diagnostics business unit has signed an exclusive distribution agreement with MedCaptain Medical Technology Co., Ltd. (MedCaptain, www.medcaptain.com/en/), a leading innovator in the fields of infusion management, in-vitro diagnostics, and rehabilitation care in the Chinese market.  Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA and CFDA cleared,... 
 Printer Friendly Version
11/10/2016Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2017 Cash Dividend Rate, and Reaffirms Fiscal 2017 Guidance
GENERAL HIGHLIGHTS CINCINNATI, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fourth quarter and full-year fiscal 2016 net revenues of $47.0 million and $196.1 million, respectively, flat and an increase of 1%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2016 operating income of $8.9 million and $51.4 million, respectively, decreases of 33% and 8%, respectively, from the same ... 
 Printer Friendly Version
10/18/2016Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2016 Operating Results and Provides Fiscal 2017 Revenue and Earnings Guidance
CINCINNATI, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal year 2016, ended on September 30, 2016, to be approximately $196 million, an increase of 1% compared to the prior year. Diluted earnings per share are expected to be $0.75 to $0.76, including costs related to acquisition activity and costs associated with the reorganization of Diagnostics sales and marketing leadership (in the a... 
 Printer Friendly Version
10/3/2016Bioline is Certified to the ISO 13485 Quality Standard
CINCINNATI, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) is proud to announce that the London R&D and Berlin manufacturing facilities are now fully accredited to the ISO 13485 quality standard. Bioline recognizes the importance of adhering to a quality management system in the development, manufacture and supply of test components to the molecular diagnostic arena. We are committed to strengthening our r... 
 Printer Friendly Version
9/26/2016Meridian Expands Molecular Test Technology License with Eiken Chemical Co., Ltd.
CINCINNATI, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced it has completed an amendment to the license agreement with Eiken Chemical Co., Ltd., Japan, for its “LAMP” (Loop-mediated Isothermal Amplification) technology for the expanded areas of animal, food and water testing.  The LAMP technology is a leading nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single temperature.  Unlike other amplif... 
 Printer Friendly Version
9/20/2016Bioline Launches New SensiFAST™ Lyo-Ready No-ROX Mix
CINCINNATI, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFAST Lyo-Ready No-ROX Mix from Bioline to add to the SensiFAST family of real-time PCR products. Bioline has developed a ready-to-use, lyophilization-compatible qPCR mix, the SensiFAST Lyo-Ready No-ROX Mix. The SensiFAST Lyo-Ready No-ROX Mix has exactly the same fast, highly reproducible performanc... 
 Printer Friendly Version
8/25/2016Meridian Malaria Test Wins Prestigious Innovation Award
illumigene® Malaria Receives 1st Place Award at the  Journées Internationales de Biologie /Association des Colloques Nationaux des Biologistes Conference in Paris CINCINNATI, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) was awarded 1st place for innovation in emergency treatment and point-of-care testing for its illumigene® Malaria test at the 2016 JIB/ACNBH Conference. Innovations from worldwide companies contributing to the development of the Medical Biology... 
 Printer Friendly Version
8/23/2016Meridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products
CINCINNATI, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of their Analyte Specific Reagent (ASR) product line. The first ASR products include a primer set and probes for detection of Helicobacter pylori and the target sequence associated with Clarithromycin-resistant H. pylori strains. Richard L. Eberly, President, Chief Commercial Officer stated, “As a consistent innovator and market share leader for in vitro diagnostic devices, it is... 
 Printer Friendly Version
8/9/2016Magellan Diagnostics Receives CFDA Clearance for LeadCare® II in China
Simple, portable diagnostic instrument used in thousands of US clinics will provide three-minute blood lead testing results to Chinese clinicians and parents CINCINNATI, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced Magellan Diagnostics, a business unit of Meridian Bioscience, has received clearance from the China Food and Drug Administration (CFDA) for its LeadCare II Blood Lead Testing System.  The system is small, portable, and produces a quantit... 
 Printer Friendly Version
7/28/2016Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, July 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2016 third quarter and first nine months net revenues of $50.7 million and $149.1 million, respectively, increases of 5% and 1%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $13.7 million, a decrease of 5% from the same period of the prior fiscal year; reported nine months operating inco... 
 Printer Friendly Version
6/15/2016Meridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae
CINCINNATI, June 15, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene® Mycoplasma Direct assay, launched earlier this year in Europe, features a simplified 3-step procedure. The new procedure will significantly expand Meridian’s customer base by eliminating the need for specialized techniques and training, as well as pr... 
 Printer Friendly Version
6/2/2016Bioline Launches New MyTaq™ Plant-PCR Kit
CINCINNATI, June 02, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq™ Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq™ Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest... 
 Printer Friendly Version
4/28/2016Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today: reported fiscal 2016 second quarter and first six months net revenues of $51.3 million and $98.4 million, respectively, decreases of 1% from the same periods of the prior fiscal year; reported second quarter operating income of $15.2 million (including $1.2 million of costs associated with acquisition activity), a decrease of 4% from the same period of the prior fiscal... 
 Printer Friendly Version
4/27/2016Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
illumigene® Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay features a simplified procedure compared to the existing illumigene Mycoplasma product. The new procedure... 
 Printer Friendly Version
3/24/2016Meridian Bioscience Acquires Magellan Diagnostics, Inc.
CINCINNATI, March 24, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults. Today, Magellan is the l... 
 Printer Friendly Version
3/3/2016Bioline Launches New EPIK™ miRNA Select Kits
CINCINNATI, March 03, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the EPIK™ miRNA Select Assays, developed for study of individual microRNA (miRNA) molecules. The EPIK miRNA Select Kits compliment the EPIK miRNA Panel Assays released at the end of 2015 and demonstrates the continued collaboration between MiRXES in Singapore and Bioline.  Recent studies continue to show the... 
 Printer Friendly Version
1/27/2016Meridian Bioscience Reports First Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
GENERAL HIGHLIGHTS CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported first quarter net revenues of $47.2 million, a decrease of 2% from the same period of the prior fiscal year; reported first quarter operating income of $13.6 million, an increase of 7% from the same period of the prior fiscal year; reported first quarter net earnings of $8.9 million, or $0.21 per diluted share, increases of 13% and 11... 
 Printer Friendly Version
1/26/2016Meridian Bioscience and Lean Continuous Improvements, LLC Collaborate to Apply Lean Principles to Recent Launch of illumigene® Malaria
CINCINNATI, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. announced today that the recent product transfer and launch of its innovative molecular test illumigene® Malaria was accomplished on an accelerated schedule via a collaboration with Lean Continuous Improvements, LLC (LCI).  The development and transfer of medical devices is a complicated and highly regulated process.  Meridian recognized the need to streamline the tasks and activities required to move a new test from the p... 
 Printer Friendly Version
1/26/2016New Malaria Test, illumigene® Malaria, Sets a New Gold Standard for Diagnosis
Meridian Bioscience Collaborates With the Centers for Disease Control and Prevention and Cheikh Anta Diop University of Dakar to Launch Diagnostic Test up to 80,000 Times More Sensitive Than Current Options CINCINNATI, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received the CE Mark for illumigene® Malaria, a novel, highly accurate  test developed by Meridian with the technical assistance of the Centers for Disease Control and Preventi... 
 Printer Friendly Version
12/9/2015Bioline Launches New JetSeq™ DNA Library Preparation Kit
CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the JetSeq™ DNA Library Preparation Kit, the first product in a new line of kits from Bioline for Next Generation Sequencing (NGS) sample preparation. Developed in collaboration with Oxford Gene Technology (OGT), the JetSeq DNA Library Preparation Kit uses ... 
 Printer Friendly Version
11/18/2015Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims
CINCINNATI--(BUSINESS WIRE)--Nov. 18, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for new claims for its illumigene® Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab™ (Copan Diagnostics, Inc.). ... 
 Printer Friendly Version
11/12/2015Meridian Bioscience Announces Investment in Oasis Diagnostics®
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has made a minority investment in Oasis Diagnostics® Corporation ("Oasis"), with the right to acquire Oasis in the future. The terms of the transaction were not disclosed. Oasis designs, develops, manufactures and sells pre-analytic tools for the collection, preservation, and transportation of saliva/oral fluids. ... 
 Printer Friendly Version
11/5/2015Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 5, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fourth quarter and record full-year fiscal 2015 net revenues of $47.1 million and $194.8 million, respectively, increases of 1% and 3%, respectively, from the same periods of the prior fiscal year; reported fourth q... 
 Printer Friendly Version
9/9/2015Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2016
CINCINNATI--(BUSINESS WIRE)--Sep. 9, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2016 net revenues and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2016, management expects net revenue growth of 3% to 5% on a constant currency basis, a net revenue range of $195 to $200 million, and per s... 
 Printer Friendly Version
9/4/2015Bioline Launches New EPIK™ miRNA Panel Assays
CINCINNATI--(BUSINESS WIRE)--Sep. 4, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the EPIK™ miRNA Panel Assays, developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of a collaboration between MiRXES in Singapore and Bioline. Using a novel approach developed by MiRXES, comb... 
 Printer Friendly Version
8/17/2015Meridian Bioscience Elects Catherine Sazdanoff and John McIlwraith to the Board of Directors
CINCINNATI--(BUSINESS WIRE)--Aug. 17, 2015-- Meridian Bioscience, Inc. announces that on August 11, 2015, the Board of Directors of Meridian Bioscience, Inc. elected two new independent directors, Catherine A. Sazdanoff and John C. McIlwraith, effective August 14, 2015. Ms. Sazdanoff is the CEO and President of Sazdanoff Consulting LLC, specializing in business development, management and strategy consulting. In addition, she is Strategic ... 
 Printer Friendly Version
7/23/2015Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 23, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fiscal 2015 third quarter and first nine months net revenues of $48.2 million and $147.8 million, respectively, increases of 2% and 4%, respectively, from the same periods of the prior fiscal year; reported third quarter operating i... 
 Printer Friendly Version
7/20/2015Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® HSV 1&2
CINCINNATI--(BUSINESS WIRE)--Jul. 20, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its illumigene® molecular platform. The illumigene® HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the US – they are the eighth and ninth assays added to ... 
 Printer Friendly Version
6/4/2015Meridian Bioscience Launches Para-Pak® SVT (Single Vial Transport)
CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the launch of Para-Pak® SVT, a one-vial, multi-purpose, transport solution for the collection, transportation, preservation and examination of intestinal parasites in stool specimens. Traditional Ova & Parasite (O&P) examination procedures, as well as fecal antigen immunoassay tests, require different types of preservative... 
 Printer Friendly Version
5/21/2015Meridian Bioscience Europe Launches New Molecular Tests for the Detection of Herpes Simplex Virus Type 1 and Type 2
CINCINNATI--(BUSINESS WIRE)--May 21, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received the CE Mark for new molecular assays for the detection of Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its molecular platform, illumigene®. The HSV 1&2 assays are additions to the portfolio of molecular tests available for use on the illumigene platform; including C. difficile, Chlamydia, Group A Str... 
 Printer Friendly Version
4/23/2015Meridian Bioscience Reports Second Quarter 2015 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 23, 2015-- Meridian Bioscience, Inc., (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., (NASDAQ: VIVO) today: reported record fiscal 2015 second quarter and first six months net revenues of $51.5 million and $99.6 million, respectively, increases of 3% and 5%, respectively, from the same periods of the prior fiscal year; reported second q... 
 Printer Friendly Version
3/11/2015Bioline Launches Latest ISOLATE II miRNA and RNA Purification Kits
CINCINNATI--(BUSINESS WIRE)--Mar. 11, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the latest five kits in the high performance ISOLATE II nucleic acid purification range – ISOLATE II miRNA, Plant miRNA, Biofluids RNA, RNA/DNA/Protein, and FFPE RNA/DNA Kits. Based on the latest developments in silica membrane spin column technology and o... 
 Printer Friendly Version
2/26/2015Meridian Bioscience Launches New TRU Brand Test for the Detection of Streptococcus pneumoniae in Urine and CSF
CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announces that it has received the CE Mark for its new test for Streptococcus pneumoniae (S. pneumo). TRU STREP PNEUMO™ is a rapid, qualitative immunoassay for the detection of S. pneumo antigen in urine and CSF and will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribut... 
 Printer Friendly Version
2/26/2015Meridian Bioscience Receives CE Marking for Two New Molecular Amplification Tests: illumigene® Chlamydia and illumigene® Gonorrhea
CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), the sixth and seventh assays on the illumigene® platform. Along with these two new assays, Meridian also received the CE Mark for an innovative, simple, fast and cost effective sample preparation ... 
 Printer Friendly Version
1/22/2015Meridian Bioscience Reports First Quarter 2015 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: Reported record first quarter net revenues of $48.0 million, an increase of 7% from the same period of the prior fiscal year; reported first quarter operating income of $12.7 million, an increase of 9% from the same period of the prior fisca... 
 Printer Friendly Version
1/9/2015Meridian Opens a New Office in Beijing, China
CINCINNATI--(BUSINESS WIRE)--Jan. 9, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) has opened a new office in Beijing, China. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) on the 15th floor in the New China Life Insurance (NCI) Tower Center, in the heart of the central business district (CBD) of Beijing. ... 
 Printer Friendly Version
12/2/2014Meridian Life Science Awarded SBIR II by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2014-- Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce they have been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development... 
 Printer Friendly Version
11/6/2014Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 6, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fourth quarter and full-year fiscal 2014 net revenues of $46.7 million and $188.8 million, respectively, a decrease of 5% and an increase of less than 1%, respectively, from the same periods of the prior fiscal year; reporte... 
 Printer Friendly Version
9/3/2014Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2014-- Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. diffic... 
 Printer Friendly Version
9/2/2014Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 2, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2015 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted ... 
 Printer Friendly Version
8/6/2014Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
CINCINNATI--(BUSINESS WIRE)--Aug. 6, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes. ... 
 Printer Friendly Version
7/24/2014Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 24, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fiscal 2014 third quarter and first nine months net sales of $47.2 million and $142.1 million, respectively, flat and an increase of 2%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $13.1 million, a decrease of 16% from the same period of the prior fisca... 
 Printer Friendly Version
5/28/2014Meridian Bioscience Receives Canadian Licenses for illumigene® Mycoplasma and illumigene® Pertussis
CINCINNATI--(BUSINESS WIRE)--May 28, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene® molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing so... 
 Printer Friendly Version
4/24/2014Meridian Bioscience Reports Second Quarter 2014 Operating Results and Revises Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 24, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported record fiscal 2014 second quarter and first six months net sales of $50.1 million and $94.9 million, respectively, increases of 6% and 2%, respectively, from the same periods of the prior fiscal year; reported second quarte... 
 Printer Friendly Version
3/27/2014Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Pertussis
CINCINNATI--(BUSINESS WIRE)--Mar. 27, 2014-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today’s healthcare market. ... 
 Printer Friendly Version
2/18/2014Bioline Launches New Products for Epigenetics Research
CINCINNATI--(BUSINESS WIRE)--Feb. 18, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the rapidly growing Epigenetics field, with the launch of the first kits in the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™ Amplification Kit. These EPIKTM Kits have been developed to meet the needs of researchers employing PCR and real-time PCR analy... 
 Printer Friendly Version
2/7/2014Bioline Launches High Performance SensiFAST™ cDNA Synthesis Kit
CINCINNATI--(BUSINESS WIRE)--Feb. 7, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the SensiFASTTM cDNA synthesis kit. Powered by a newly developed Reverse Transcriptase enzyme with enhanced properties and in combination with the unique TransAmp™ buffer; SensiFASTTM cDNA synthesis kit is the choice for scientists who need consistent, unbiased, fi... 
 Printer Friendly Version
1/22/2014Meridian Bioscience Reports First Quarter 2014 Operating Results, Declares Increased Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported first quarter net sales of $44.8 million, a decrease of 1% from the same period of the prior fiscal year; reported first quarter operating income of $11.6 million, a decrease of 11% from the same period of the prior fiscal year; reported first quarter net earnings of $7.4 million, or $0.18 per ... 
 Printer Friendly Version
1/15/2014Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced weaker than expected preliminary operating results for the first quarter ended December 31, 2013. Fiscal 2014 First Quarter Preliminary Outlook Due to factors including reduced hospital admissions and declining C. difficile incidence rates in hospitals putting further pressure on an already competitive market, Life Science shipment... 
 Printer Friendly Version
1/14/2014Bioline Expands into Singapore
CINCINNATI--(BUSINESS WIRE)--Jan. 14, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an office in Singapore to support and grow the Bioline business in Singapore and in Asia. With the opening of the new office; Bioline will provide direct sales, technical support, and training to its existing customers and can also offer a same-day delivery to many ... 
 Printer Friendly Version
1/10/2014Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU® to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim
CINCINNATI--(BUSINESS WIRE)--Jan. 10, 2014-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the company’s TRU FLU® assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU® is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. New strains of Influenza viruses are continuously emerging to ... 
 Printer Friendly Version
11/14/2013PCR from Whole Blood, Simplified
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Blood-PCR Kit, developed for fast, highly-specific PCR direct from whole blood samples. Based on the proven MyTaqTM HS DNA polymerase, in combination with a novel, red-colored, buffer system; the new Bioline MyTaqTM Blood-PCR Kit overcomes the ... 
 Printer Friendly Version
11/7/2013Meridian Bioscience Reports Record Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate for Fiscal 2014, and Reaffirms Fiscal 2014 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 7, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2013 net sales of $49.0 million and $188.7 million, respectively, increases of 13% and 9%, respectively, from the same periods of the prior fiscal year; reported record f... 
 Printer Friendly Version
10/31/2013Meridian Life Science Awarded SBIR by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine
MEMPHIS, Tenn.--(BUSINESS WIRE)--Oct. 31, 2013-- Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), has been selected by the Centers for Disease Control and Prevention (CDC) to develop a process for manufacture of a rotavirus vaccine. Funding for this activity will be provided through a Small Business Innovation Research (SBIR) contract. Process development will focus on optimiz... 
 Printer Friendly Version
9/9/2013Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 9, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2014 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2014, management expects net sales to be in the range of $203 to $208 million and per share diluted earnings to be between $0.98 ... 
 Printer Friendly Version
7/25/2013Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 25, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2013 third quarter and nine months net sales of $47.1 million and $139.7 million, respectively, increases of 12% and 8%, respectively, from the same periods of the prior fiscal year; reported third quarter o... 
 Printer Friendly Version
7/2/2013Bioline Launches the MyTaq™ Extract-PCR Kit, Single Tube Extraction of PCR-Ready DNA from Mammalian Tissues
CINCINNATI--(BUSINESS WIRE)--Jul. 2, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaqTM Extract-PCR Kit. Powered by the high performance MyTaqTM DNA Polymerase, the MyTaqTM Extract-PCR Kit offers a quick and easy alternative for the extraction and amplification of DNA from a variety of mammalian tissue types. Researchers using the ... 
 Printer Friendly Version
6/10/2013Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Mycoplasma
CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae), its fourth assay on the illumigene platform. This innovative test that aids in identifying an important respiratory pathogen is a strong addition to the illumigene platform. Often referred to as “walking pneumo... 
 Printer Friendly Version
4/25/2013Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 25, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2013 second quarter and six months net sales of $47.3 million and $92.6 million, respectively, flat and an increase of 6%, respectively, from the same periods of the prior fiscal year; reported second quar... 
 Printer Friendly Version
3/28/2013Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies
CINCINNATI--(BUSINESS WIRE)--Mar. 28, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has been recognized by Forbes as one of America’s 100 Most Trustworthy Companies. The list is selected following a comprehensive evaluation of governance and accounting practices of candidate companies having market capitalization over $250 million. The rankings are based on data from GMI Ratings (GMI) that looks at over 60 governance and account... 
 Printer Friendly Version
3/18/2013Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA
CINCINNATI--(BUSINESS WIRE)--Mar. 18, 2013-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the U.S. Food & Drug Administration (FDA) has re-categorized Meridian’s illumigene® Group A Streptococcus and illumigene® Group B Streptococcus tests as “Moderate Complexity” under the Clinical Laboratory Improvement Amendments (CLIA). Moderately complex tests are assays that are considered to be simple and easy to use. ... 
 Printer Friendly Version
2/6/2013Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation
CINCINNATI--(BUSINESS WIRE)--Feb. 6, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the high performance ISOLATE II range of nucleic acid purification kits. Based on filter membrane spin column technology with simple bind-wash-elute steps; the new Bioline ISOLATE II kits are designed for fast and efficient isolation of DNA or RNA from ... 
 Printer Friendly Version
1/23/2013Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 23, 2013-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record first quarter net sales of $45.4 million, an increase of 13%, from the same period of the prior fiscal year; reported first quarter operating income of $13.1 million, an increase of 34%, over the same pe... 
 Printer Friendly Version
12/13/2012Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests
CINCINNATI--(BUSINESS WIRE)--Dec. 13, 2012-- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has successfully completed beta trials for two new illumigene molecular amplification tests. These assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae, respectively, from both swab and urine samples. For the first time, these two new assays will also incorporate Meridian Bioscience’s new... 
 Printer Friendly Version
12/4/2012Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012
CINCINNATI--(BUSINESS WIRE)--Dec. 4, 2012-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced that its Board of Directors today declared an accelerated cash dividend of $0.19 per share payable on December 24, 2012 to shareholders of record on December 14, 2012. The declaration and payment of this cash dividend is in lieu of the regular quarterly cash dividend that would have normally been paid in February 2013. The a... 
 Printer Friendly Version
11/28/2012SensiFAST™ Genotyping Kit Exceed the Limit
CINCINNATI--(BUSINESS WIRE)--Nov. 28, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of SensiFAST Genotyping Kit, which has been specifically developed for the important field of genotyping. Bioline’s SensiFAST Genotyping Kit has been developed for fast, precise, and highly reproducible genotyping of sequence variants, including loci with... 
 Printer Friendly Version
11/8/2012Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2012-- Meridian Bioscience, Inc.: GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2012 net sales of $43.7 million and $173.5 million, respectively, increases of 6% and 9%, respectively, from the same periods of the prior fiscal year; reported record fourth quarter ... 
 Printer Friendly Version
9/17/2012Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group A Strep
CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2012-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene® platform. Group A Streptococcus is a bacterium commonly found in the human throat or on skin and causes a wide variety of diseases in humans, the most common being acute pharyngitis or strep throat. Grou... 
 Printer Friendly Version
8/28/2012Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2013 and Reaffirms Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2013 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2013, management expects net sales to be in the range of $190 to $195 million and per share diluted earnings to be between $0.86 and $0.91. Th... 
 Printer Friendly Version
7/26/2012Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 26, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2012 third quarter and nine months net sales of $42.1 million and $129.8 million, respectively, increases of 5% and 10%, respectively, from the same periods of the prior fiscal year; reported third quart... 
 Printer Friendly Version
7/17/2012Meridian Bioscience, Inc. to Release Fiscal 2012 Third Quarter and Nine Months Operating Results on July 26
CINCINNATI--(BUSINESS WIRE)--Jul. 17, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of its fiscal 2012 third quarter and nine months operating results on Thursday, July 26 at approximately 7:15 a.m. (Eastern). Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers ... 
 Printer Friendly Version
4/26/2012Meridian Bioscience Reports Record Second Quarter and First Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI, Apr 26, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fiscal 2012 second quarter and six months net sales of $47.4 million and $87.7 million, respectively, increases of 16% and 12%, respectively, from the same periods of the prior fiscal year; reported record second quarter operating income ... 
 Printer Friendly Version
4/12/2012Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C. difficile and Group B Streptococcus
CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has signed a new group purchasing agreement with the Premier healthcare alliance to offer illumigene(R) C. difficile and illumigene Group B Streptococcus to its members at specially negotiated pricing. Premier serves more than 2,500 U.S. hospitals and 81,000-plus other healthcare sites. This agreement allows Premier alliance facilities to implemen... 
 Printer Friendly Version
4/12/2012Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26
CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of its 2012 second quarter financial results for Thursday, April 26 at approximately 7:45 a.m. (Eastern). ABOUT MERIDIAN BIOSCIENCE, INC. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmace... 
 Printer Friendly Version
3/21/2012Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene(R) Group B Streptococcus
CINCINNATI, Mar 21, 2012 (BUSINESS WIRE) --Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform. The approval in Australia for the commercialization of illumigene GBS, comes on the heels of the recent FDA ... 
 Printer Friendly Version
3/21/2012Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene® Group B Streptococcus
CINCINNATI--(BUSINESS WIRE)--Mar. 21, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform. The approval in Australia for the commercialization of illumigene GBS, comes on the heels of the rece... 
 Printer Friendly Version
3/20/2012Bioline Celebrates 20 Years of Service to Life Science
CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), was founded in London, UK in 1992 by Marco Calzavara, President of Meridian Bioscience Europe. Bioline is a leading manufacturer and distributor of PCR enzymes and molecular biology reagents providing complete solutions to researchers in universities, major research institutions, hospitals, biotech and ph... 
 Printer Friendly Version
2/27/2012Meridian Bioscience Receives FDA Clearance for New Legionella Test
CINCINNATI--(BUSINESS WIRE)--Feb. 27, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella™, a new rapid assay for detection of legionellosis. TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup 1 that is most commonly associated with Legionnaire’s disease. Suspected infectio... 
 Printer Friendly Version
2/16/2012Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis
CINCINNATI--(BUSINESS WIRE)--Feb. 16, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its SensiFAST family real-time PCR products. SensiFAST HRM Kit facilitates High Resolution Melt (HRM) curve analysis, enabling amplification and discrimination of even the most challenging sequence differences (such as class 4 SNPs) without sequence preference.... 
 Printer Friendly Version
1/25/2012Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 25, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported first quarter net sales of $40.3 million, an increase of 8% from the same period of the prior fiscal year; reported first quarter operating income of $9.8 million, an increase of 8% over the same period of the prior fiscal year; reported first quarter net earnings of $6.6 million, or $0.16 per diluted shar... 
Download PDFPrinter Friendly Version
1/18/2012Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker
CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its HyperPAGE range of prestained molecular weight protein markers. HyperPAGE II contains 9 highly purified protein bands from 10 to 250kDa prestained with different fluorescence dyes to facilitate easy identification and orientation whether performing protein ... 
 Printer Friendly Version
12/27/2011Meridian Bioscience Receives FDA Clearance For ImmunoCard® C. difficile GDH Test
CINCINNATI--(BUSINESS WIRE)--Dec. 27, 2011-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard® C. difficile GDH. This test detects the C. difficile common antigen glutamate dehydrogenase (or GDH). This assay has already been successfully launched and accepted in global markets as an excellent screening option for C. difficile. The GDH commo... 
 Printer Friendly Version
12/12/2011Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group B Streptococcus
CINCINNATI--(BUSINESS WIRE)--Dec. 12, 2011-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Group B Streptococcus (GBS) on the illumigene® platform. This innovative test is a strong addition to the illumigene platform. Group B Streptococcus, or GBS, continues to be a major perinatal pathogen, for both mothers and their infants, and is associa... 
 Printer Friendly Version
11/10/2011Meridian Bioscience Reports Fourth Quarter and Full-Year 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI, Nov 10, 2011 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fourth quarter and record full-year fiscal 2011 net sales of $41.3 million and $159.7 million, respectively, increases of 16% and 12%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2011 operating income of $9.9 million and $40.0 million, respective... 
Download PDFPrinter Friendly Version
8/25/2011Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2012 and Comments on Fiscal 2011 Guidance
CINCINNATI, Aug 25, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2012 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2012, management expects net sales to be in the range of $183 to $192 million and per share diluted earnings to be between $0.85 and $0.89. The per ... 
 Printer Friendly Version
8/23/2011Meridian Bioscience Establishes Direct Sales in Australia Through Bioline Australia
CINCINNATI, Aug 23, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., (NASDAQ: VIVO) is pleased to announce the commencement of a new, direct distribution arrangement in Australia for the Meridian diagnostic products. Meridian is transitioning the sales of the Meridian diagnostic products from its current distributor to its direct sales force through Bioline (Aust) Pty Ltd. (Bioline Australia), a wholly-owned subsidiary of Meridian Bioscience, Inc. Bi... 
 Printer Friendly Version
8/9/2011Meridian Bioscience Launches ImmunoCard(R)C. difficile GDH Assay in Europe
CINCINNATI, Aug 09, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ:VIVO) is pleased to announce the launch of a new Clostridium difficile rapid test, ImmunoCardC. difficile GDH. This assay detects the common antigen, Glutamate dehydrogenase, produced by toxigenic and non-toxigenic strains of Clostridium difficile. Toxigenic strains of Clostridium difficile are frequently associated with hospital and community acquired diarrhea and can lead to lif... 
 Printer Friendly Version
7/21/2011Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2011 Guidance
CINCINNATI, Jul 21, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2011 third quarter and nine months net sales of $40.1 million and $118.4 million, respectively, increases of 18% and 10%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income of $10.1 million, a... 
 Printer Friendly Version
6/10/2011Meridian Tests Detect Deadly Toxins Produced by E. coli O104 Outbreak Strain
CINCINNATI, Jun 10, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its tests detect the deadly toxins produced by the recent outbreak strain E. coli O104:H4. E. coli O104:H4 is the novel shiga toxin-producing strain associated with a number of deaths in Europe. It has also caused hemolytic uremic syndrome (HUS) (a type of kidney failure) in hundreds of others. In the United States, one confirmed and three suspec... 
 Printer Friendly Version
6/7/2011E. coli O104 Outbreak Highlights Need for Rapid, Accurate Testing Options
CINCINNATI, Jun 07, 2011 (BUSINESS WIRE) --The recent E. coli outbreak making headlines in Europe and the United States has been identified as a rare and unique strain, E. coli O104:H4. The outbreak strain is a Shiga toxin 2 type producing E. coli, and is of concern because initial lab findings have revealed various characteristics that make it more virulent and toxin producing. The most recent statistics show that 1,674 people have been infected with... 
 Printer Friendly Version
5/10/2011Meridian Bioscience Receives FDA Clearance for New Premier (TM) C. difficile GDH Assay
CINCINNATI, May 10, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new Clostridium difficile immunoassay named Premier(TM) C. difficile GDH. This product expands the Company's existing portfolio of C. difficile tests and has been available in Europe and the rest of world since October of 2010. The assay detects a c... 
 Printer Friendly Version
4/21/2011Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Apr 21, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year; reported second quarter operating income of $11.0 million, an... 
 Printer Friendly Version
3/2/2011Meridian Bioscience Receives FDA Clearance For New illumigene(R)C. difficile Pediatric Claim
CINCINNATI, Mar 02, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for a new pediatric claim for its illumigeneC. difficile (Clostridium difficile) molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflam... 
 Printer Friendly Version
1/20/2011Meridian Bioscience Reports First Quarter 2011 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Jan 20, 2011 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported first quarter net sales of $37.3 million, a decrease of 12%, from the same period of the prior fiscal year; reported first quarter operating income of $9.1 million, a decrease of 34%, from the same period of the prior fiscal year; ... 
 Printer Friendly Version
11/11/2010Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2010 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2011 Guidance
CINCINNATI, Nov 11, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS reported fourth quarter and full-year fiscal 2010 net sales of $35.5 million and $143.0 million, respectively, decreases of 16% and 4%, respectively, from the same periods of the prior fiscal year; reported fourth quarter and full-year fiscal 2010 operating income of $8.5 million and $41.1 million, respectively, dec... 
 Printer Friendly Version
9/30/2010Meridian Bioscience Receives Canadian License for illumigene(TM) C. difficile
CINCINNATI, Sep 30, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin p... 
 Printer Friendly Version
9/13/2010Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2011 and Updates Fiscal 2010 Guidance
CINCINNATI, Sep 13, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2011 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2011, management expects net sales to be in the range of $165 to $170 million and per share diluted earnings to be between $0.77 and $0.82. The per share estimates assume ... 
Download PDFPrinter Friendly Version
7/20/2010Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2010 Guidance
CINCINNATI, Jul 20, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported third quarter net sales of $33.9 million, a decrease of 11% compared to the same period of the prior fiscal year; reported record nine months net sales of $107.5 million, an increase of 2%, compared to the same period of the prior fiscal year; reported third quarter and nine months operating income of $9.8... 
Download PDFPrinter Friendly Version
7/20/2010Meridian Bioscience Acquires Leading Manufacturer and Distributor of Molecular Reagents
CINCINNATI, Jul 20, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand. Bioline, headquartered in London, is a leading manufacturer and distributor of molecula... 
Download PDFPrinter Friendly Version
7/13/2010Meridian Bioscience Receives FDA Clearance for New illumigene(TM) Molecular Platform
CINCINNATI, Jul 13, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its new molecular amplification assay, illumigene(TM) C.difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon. The illumigene molecular amplification assay detects the presence of the toxin producing region from... 
Download PDFPrinter Friendly Version
7/7/2010Meridian Bioscience, Inc. Enters into Product Development and Distribution Agreement with DiaSorin S.p.A.
CINCINNATI, Jul 07, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has entered into an exclusive, world-wide product development and distribution agreement with DiaSorin S.p.A. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop several infectious disease products for use on their LIAISON(R) systems. LIAISON is a fully automated, random access system based on chemiluminescense detection. There are ov... 
Download PDFPrinter Friendly Version
4/20/2010Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2010 Guidance
CINCINNATI, Apr 20, 2010 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported second quarter net sales of $31.1 million, a decrease of 6% compared to the same period of the prior fiscal year; reported record six months net sales of $73.6 million, an increase of 9%, compared to the same period of the prior fiscal year; reported second quarter and six months operating income of $9.1 mi... 
Download PDFPrinter Friendly Version
3/22/2010Meridian Bioscience Submits New illumigene(TM) Molecular C. difficile Test to U.S. FDA for Marketing Clearance
CINCINNATI, Mar 22, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. announced today that it has submitted a 510(k) application to the United States Food and Drug Administration for marketing clearance of its new, simple molecular diagnostic test, illumigene(TM) C. difficile. illumigene is a simplified new technology platform, based upon loop amplification (LAMP) that makes molecular diagnostic testing possible for any size laboratory. The technology is isothermal and therefore requires no cost... 
Download PDFPrinter Friendly Version
3/17/2010Meridian Bioscience Revises Guidance for Fiscal 2010 and Comments on Preliminary Second Quarter Operating Results and Business Outlook Including illumigene(TM) Update
CINCINNATI, Mar 17, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in ... 
Download PDFPrinter Friendly Version
1/21/2010Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2010 Guidance
CINCINNATI, Jan 21, 2010 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record first quarter net sales of $42.5 million, an increase of 24%, over the same period of the prior fiscal year; reported record first quarter operating income of $13.8 million, an increase of 13%, over the same period of the prior fiscal year; reported record first quarter earnings and diluted earnings... 
Download PDFPrinter Friendly Version
11/12/2009Meridian Bioscience Reports Record Fiscal 2009 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2009 net sales of $42.5 million and $148.3 million, respectively, increases of 16% and 6%, respectively, over the same periods of the prior fiscal year; reported recor... 
 Printer Friendly Version
9/30/2009Meridian Bioscience Europe Announces Agreement to Distribute Test For GI Disease
CINCINNATI--(BUSINESS WIRE)--Sep. 30, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that Meridian Bioscience Europe srl, Milan, Italy has signed an agreement with BÜHLMANN Laboratories AG, Schönenbuch, Switzerland for distribution in Italy of an innovative test for inflammatory conditions of the intestine, Quantum Blue® Calprotectin. The test which detects calprotectin, a GI inflammatory marker, is a fundamental to... 
 Printer Friendly Version
9/17/2009Meridian Bioscience Granted Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim to the TRU FLU(R) Test Package Insert
CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the company has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1 virus cultured from positive respiratory specimens. TRU FLU is a rapid test which identifies influenza A and B in human specimens. Meridian’s T... 
 Printer Friendly Version
9/15/2009Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2010 and Reaffirms Fiscal 2009 Guidance
CINCINNATI--(BUSINESS WIRE)--Sep. 15, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2010 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2010, management expects net sales to be in the range of $160 to $165 million and per share diluted earnings to be between $0.90 a... 
 Printer Friendly Version
9/3/2009Meridian Bioscience to Present at the Robert W. Baird 2009 Health Care Conference
CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 1:45 p.m. ET at the Four Seasons Hotel New York. Jack Kraeutler, Chief Executive Officer, and Bill Motto, Executive Chairman of the Board, are scheduled to present. A question and answer session will foll... 
 Printer Friendly Version
7/16/2009Meridian Bioscience Appoints James M. Anderson to Board of Directors
CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has appointed James M. Anderson to its Board of Directors effective immediately. Mr. Anderson is President and Chief Executive Officer of Cincinnati Children’s Hospital Medical Center. His appointment as President and CEO in 1996 followed 20 years of service to the Cincinnati Children’s board of ... 
 Printer Friendly Version
7/16/2009Meridian Bioscience Reports Record Sales and Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2009 Guidance, and Comments on Timing of Fiscal 2010 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record quarterly and nine-month sales of $38.2 million and $105.8 million, respectively, increases of 16% and 3% over the same periods of the prior fiscal year; reported record quarterly and nine-month operating income of $12.5 million and $35.7 million, respectively, increases of 14% and ... 
 Printer Friendly Version
7/7/2009FORTUNE Small Business Again Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 34 on their ninth annual FSB 100 list of the fastest growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/. To compile th... 
 Printer Friendly Version
6/10/2009Meridian Bioscience to Present at the William Blair and Company's 29th Annual Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has been invited to present at the William Blair and Company’s 29th Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive Officer, and Bill Motto, Executive Chairman of the Board, are scheduled to present. A question and answer session will f... 
 Printer Friendly Version
6/4/2009Meridian Bioscience Wins GHX 2009 Best in Class Award
CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2009-- Meridian Bioscience (NASDAQ: VIVO) today announced that it is a recipient of a 2009 GHX Best in Class Award for achieving the highest year-over-year market share growth for distributed products in the Microbiology Reagents/Supplies product category for the 2008 calendar year. Meridian Bioscience was among the 30 leading medical-surgical product manufacturers recognized by GHX in five market... 
 Printer Friendly Version
6/3/2009Meridian Bioscience Receives FDA Clearance for New Rapid Campylobacter Test
CINCINNATI--(BUSINESS WIRE)--Jun. 3, 2009-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new rapid test for Campylobacter, ImmunoCard STAT!® CAMPY. This new test provides fast and accurate detection of Campylobacter bacteria, one of the most common causes of diarrheal illness and the most common bacterial cause of foodborne illness in the United Stat... 
 Printer Friendly Version
4/16/2009Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Revises Downward Fiscal 2009 Guidance
CINCINNATI, Apr 16, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported second quarter and six months net sales of $33.3 million and $67.6 million, respectively, decreases of 8% and 4% compared to the same periods of the prior fiscal year; reported second quarter and six months operating income of $11.0 million and $23.2 m... 
 Printer Friendly Version
2/4/2009Meridian Bioscience Receives FDA Clearance for New Campylobacter Test
CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for a new test for Campylobacter. Launched as PREMIER™ CAMPY, the rapid EIA test provides for optimized detection of Campylobacter infection, the most commonly diagnosed bacteria for food borne illness in the U.S. Approximately 20 million tests are conducted each year in the U... 
 Printer Friendly Version
1/27/2009Meridian Bioscience Announces Two New Exclusive International Distribution Agreements in Australia and Argentina
CINCINNATI, Jan 27, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the commencement of two new exclusive international distribution agreements. In Australia, Meridian has signed with Immuno Pty, Ltd, based in Sydney. For Argentina, Meridian has signed with Scott Pharma. This decision is consistent with Meridian's stated commitment to expand its non-US businesses. Over the past 25 years Immuno Pty, www.im... 
 Printer Friendly Version
1/22/2009Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2009 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2009--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record first quarter net sales of $34.3 million a 1% increase over the same period of the prior fiscal year; -- reported record first quarter net earnings of $8.1 million, an 8% increase over the same period of the prior fiscal year; -- re... 
 Printer Friendly Version
1/15/2009Meridian Bioscience, Inc. Announces Preliminary First Quarter Operating Results and Revises Fiscal 2009 Revenue Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2009--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that based on preliminary results, it expects revenues for the first quarter of fiscal 2009, ended on December 31, 2008, to be approximately $34,300,000, an increase of 1% over the prior year. During the quarter, sales to our largest distributor were essentially flat. However, shipments to customers from this distributor continued at a ... 
 Printer Friendly Version
12/10/2008Meridian Bioscience to Participate in Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Dec. 10, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that Jack Kraeutler, Chief Executive Officer, will be presenting as a panel participant at the RBC Capital Markets 2008 Healthcare Conference, held at the Westin Times Square Hotel in New York. The panel titled, Getting to the Point (of Care) is scheduled from 9-9:55 a.m. ET. on December 11, 2008 in Panel Room 2. The information prov... 
 Printer Friendly Version
12/2/2008Meridian Bioscience Announces Filing of Shelf Registration Statement to Replace Expiring Registration Statement
CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission. This registration statement replaces the Company's existing shelf registration statement originally filed in September 2003 which was scheduled to expire on December 1, 2008. This unlimited shelf registration includes common stock, preferre... 
 Printer Friendly Version
11/17/2008Meridian Bioscience to Present at theLazard Capital Markets 5th Annual Healthcare Conference
CINCINNATI, Nov 17, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 at 8:55 a.m. ET at The St. Regis, New York. Melissa Lueke, Vice President, CFO, is scheduled to present. A question and answer session will follow the Company's presentation. The information prov... 
 Printer Friendly Version
11/12/2008Meridian Bioscience Reports Record Fiscal 2008 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2008 net sales of $36.5 million and $139.6 million, respectively, increases of 13% and 14%, respectively, over the same periods of the prior fiscal year; reported record fourth quarter and full-year fiscal 2008 ... 
 Printer Friendly Version
10/30/2008New Molecular Test for C. difficile from Meridian Bioscience Expected to be Launched in Fiscal Year 2009
CINCINNATI--(BUSINESS WIRE)--Oct. 30, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced, in conjunction with the Association for Molecular Pathology 2008 Annual Meeting now occurring in Grapevine, Texas, that it anticipates launching a simple, rapid new molecular test for the toxin-producing forms of the C. difficile bacteria in the second half of fiscal year 2009. This innovative molecular test is based upon Loop Mediated Isothermal Amplification (LAMP)... 
 Printer Friendly Version
10/1/2008Meridian Bioscience to Present at the William Blair and Company Small-Cap Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the William Blair and Company Small-Cap Growth Stock Conference on Tuesday, October 7, 2008 at 12:00 p.m. ET at the Waldorf-Astoria Hotel, New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present. A question and answer session will follow the Company's presentation. The information provided during the session may n... 
 Printer Friendly Version
9/23/2008Meridian Bioscience to Present at the 2008 UBS Global Life Science Conference
CINCINNATI, Sep 23, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the 2008 UBS Global Life Science Conference at the Grand Hyatt New York in New York City. Jack Kraeutler, CEO, is scheduled to present on Wednesday, September 24, 2008 at 1:30 p.m. ET. A question and answer session will follow and some of the information provided during the session may not ... 
 Printer Friendly Version
9/10/2008Meridian Bioscience Announces New Exclusive Canadian Distribution Agreement with Somagen Diagnostics
CINCINNATI--(BUSINESS WIRE)--Sept. 10, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the commencement of a new exclusive Canadian distribution agreement with Somagen Diagnostics, Edmonton, Alberta. This decision is consistent with Meridian's stated commitment to expand its non-US businesses. Somagen Diagnostics, www.somagen.com, focuses on niche markets within the clinical diagnostic market. Like Meridian, Somagen targets markets where they can... 
 Printer Friendly Version
9/5/2008Meridian Bioscience to Present at the Robert W. Baird 2008 Small Cap Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 5, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2008 Small Cap Healthcare Conference on Wednesday, September 10, 2008 at 12:50 p.m. ET at the Intercontinental The Barclay New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present. A question and answer session will follow the Company's presentation. The information provided during t... 
 Printer Friendly Version
8/14/2008Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2009 and Reaffirms Fiscal 2008 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2009 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2009, management expects net sales to be in the range of $157 to $160 million and per share diluted earnings to be between $0.86 and $0.90. The per share estima... 
 Printer Friendly Version
7/17/2008Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2008 Guidance, and Comments on Fiscal 2009 Outlook
CINCINNATI--(BUSINESS WIRE)--July 17, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record third quarter and nine-month sales of $33.1 million and $103.2 million, respectively, increases of 11% and 14% over the same periods of the prior fiscal year; -- reported record third quarter and nine-month operating income of $11.0 million and $32.9 million, respectively, increases of 16% and 25% over the same... 
 Printer Friendly Version
6/25/2008Fortune Small Business Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies
CINCINNATI, June 25, 2008 (PRIME NEWSWIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 65 on its eighth annual FSB 100 list of the fastest-growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2008/ John A. Kraeutler, Chief Executive Officer, stated, The development, manufacture an... 
 Printer Friendly Version
6/19/2008Meridian Bioscience Completes Acquisition of Recombinant Protein Technologies and Products from Vybion, Inc.
CINCINNATI--(BUSINESS WIRE)--June 19, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has completed the purchase of technologies and products including infectious disease recombinant proteins and cardiac antigens from Vybion, Inc., highlights include: -- year 1 revenues of approximately $400,000 with attractive margins post-integration; -- purchase price of $653,000 in cash plus future royalties based on net sales of the acquired product... 
 Printer Friendly Version
5/13/2008Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.
CINCINNATI--(BUSINESS WIRE)--May 13, 2008--Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired include a portfolio of recombinant viral proteins and cardiac antigens,... 
 Printer Friendly Version
5/12/2008Meridian Bioscience to Present At the Nasdaq 21st Investor Program, London
CINCINNATI, May 12, 2008 (PrimeNewswire via COMTEX News Network) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that the Company has been invited to present at the NASDAQ 21st Investor Program, London on Wednesday, May 21, 2008 at 11:15 a.m. BST at The Andaz Hotel, London, UK. Bill Motto, Executive Chairman of the Board and Jack Kraeutler, Chief Executive Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The information provided ... 
 Printer Friendly Version
5/12/2008Meridian Bioscience to Present at the Robert W. Baird 2008 Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--May 12, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2008 Growth Stock Conference on Wednesday, May 14, 2008 at 3:05 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Executive Chairman of the Board and Jack Kraeutler, Chief Executive Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The information provided ... 
 Printer Friendly Version
4/17/2008Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results
CINCINNATI--(BUSINESS WIRE)--April 17, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record second quarter and six months net sales of $36.2 million and $70.1 million, respectively, increases of 13% and 15% over the same periods of the prior fiscal year; -- reported record second quarter and six months net earnings of $7.3 million and ... 
 Printer Friendly Version
4/9/2008Meridian Bioscience Launches Two New TRU(TM) Brand Rapid Tests for the Detection of Epstein-Barr Virus
CINCINNATI--(BUSINESS WIRE)--April 9, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has launched two new rapid tests for Epstein-Barr Virus (EBV): TRU EBV-M(TM) and TRU EBV-G(TM). The TRU EBV tests are the first rapid tests on the market which employ recombinant antigen technology to detect IgM and IgG antibodies specific to EBV. EBV is the primary cause of infectious mononucleosis and has been implicated in a number of benign and malignant disorders, incl... 
 Printer Friendly Version
3/25/2008Meridian Bioscience to Present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum
CINCINNATI--(BUSINESS WIRE)--March 25, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company has been invited to present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum at The Hyatt Regency Hotel in New York. Jack Kraeutler, Chief Executive Officer, is scheduled to present on Wednesday, March, 26, 2008 at 1:30 p.m. ET. A question and answer session will follow and some of the information prov... 
 Printer Friendly Version
1/28/2008Meridian Bioscience Promotes John A. Kraeutler to Chief Executive Officer, William J. Motto Moves to Executive Chairman
CINCINNATI--(BUSINESS WIRE)--Jan. 28, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Board of Directors has appointed Jack Kraeutler to Chief Executive Officer. Mr. Kraeutler joined the Company in January, 1992 as Executive Vice President and Chief Operating Officer. In July 1992, Mr. Kraeutler was named President and Chief Operating Officer of Meridian. Before joining Meridian, Mr. Kraeutler served as Vice President, General Manager for a di... 
 Printer Friendly Version
1/22/2008Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2008 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2008--Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS ---------------------------------------------------------------------- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: -- reported record first quarter net sales of $33.8 million an 18% increase over the same period of the prior fiscal year; -- reported record quarterly net earnings of $7.5 million, a 34% ... 
 Printer Friendly Version
11/26/2007Meridian Bioscience Receives FDA Clearance for Two New Rapid Tests for the Detection of Influenza and Respiratory Syncytial Virus
CINCINNATI--(BUSINESS WIRE)--Nov. 26, 2007--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market two new upper respiratory tests: TRU FLU(R) and TRU RSV(R). These tests are based upon a new rapid test technology that features improved safety and space savings. TRU FLU(R) detects both influenza A and influenza B while TRU RSV(R) detects for respiratory syncytial virus. These companion tests are... 
 Printer Friendly Version
11/14/2007Meridian Bioscience Reports Record Fiscal 2007 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2007--Meridian Bioscience, Inc. GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record fourth quarter and full-year fiscal 2007 net sales of $32.4 million and $123.0 million, respectively, increases of 13% over the same periods of the prior fiscal year; -- reported record fourth quarter and full-year fiscal 2007 operating income of $8.6 mi... 
 Printer Friendly Version
9/20/2007Meridian Bioscience to Present at the UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 20, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Science Conference at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present on Wednesday, September, 26, 2007 at 2:00 p.m. ET. A question and answer session will follow and some of the information provided during the ses... 
 Printer Friendly Version
9/19/2007Meridian Bioscience to Present at the Sidoti & Company, LLC Sixth Annual West Coast Emerging Growth International Investor Forum
CINCINNATI--(BUSINESS WIRE)--Sept. 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Sidoti & Company, LLC Sixth Annual West Coast Emerging Growth International Investor Forum at the Ritz-Carlton Hotel in San Francisco. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present on Monday, September, 24, 2007 at 9:40 a.m. PDT. A question and answer session will follow... 
 Printer Friendly Version
8/28/2007Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine
CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced the commencement of a Phase I/II Clinical Trial for a Parvovirus B19 Vaccine manufactured by its wholly owned subsidiary, Meridian Life Science, located in Memphis, Tennessee. The Investigational New Drug (IND) Application for the Parvovirus B19 Vaccine was a collaborative effort between Meridian Life Science and two branches of the National Institutes of Health (NIH),... 
 Printer Friendly Version
8/14/2007Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2008 and Reaffirms Fiscal 2007 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2008 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2008, management expects net sales to be in the range of $140 to $142 million and per share diluted earnings to be between $0.72 and $0.75. The per share estimat... 
 Printer Friendly Version
8/7/2007Meridian Bioscience Awarded NIH Contract for Production of Experimental Vaccines
CINCINNATI--(BUSINESS WIRE)--Aug. 7, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) was awarded a five year contract (base year plus 4 option years) having a value of up to $12.2 million by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Meridian will manufacture up to 10 clinical experimental vaccines per year at its bioph... 
 Printer Friendly Version
7/19/2007Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2007 Guidance, and Comments on Fiscal 2008 Outlook
CINCINNATI--(BUSINESS WIRE)--July 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record third quarter and nine-month sales of $29,763,000 and $90,577,000, respectively, an increase of 12% and 14% over the same periods of the prior fiscal year; -- reported record third quarter and nine-month operating income of $9,473,000 and $26,350,000, respectively, an increase of 37% and 31% over the same period... 
 Printer Friendly Version
6/5/2007Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2007
CINCINNATI--(BUSINESS WIRE)--June 5, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2007 earnings from a range of $0.55 to $0.58 per share (as adjusted for the May 11, 2007 three-for-two stock split) to a new range of $0.57 to $0.60 per share. The per share estimates assume an increase in average shares outstanding from approximately 40.2 million at fiscal 2006 year end to 40.5 million at fiscal 2007 year end. Net sales... 
 Printer Friendly Version
5/3/2007Meridian Bioscience to Present at the Robert W. Baird 2007 Growth Stock Conference
CINCINNATI, May 03, 2007 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2007 Growth Stock Conference on Thursday, May 10, 2007 at 12:35 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The informa... 
 Printer Friendly Version
4/19/2007Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Splits Stock 3 for 2, and Increases Dividend
General Highlights CINCINNATI--(BUSINESS WIRE)--April 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record second quarter and six months net sales of $32,094,000 and $60,814,000, respectively, an increase of 14% over the same periods of the prior fiscal year; reported record second quarter and six months net earnings of $5,881,000 and $11,445,000, respectively, an increase of 25% and 32% over ... 
 Printer Friendly Version
2/20/2007Meridian Bioscience Receives FDA Clearance for New E. coli Test
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!® EHEC, a revolutionary new test for the diagnosis of E. coli infection. The new product detects all Shiga-toxin producing E. coli and is the first rapid (20 minute) E. coli diagnostic that differentiates between Toxin 1 & Toxin 2. With the recent national E. coli outbreaks (spinach in September 2006 and lettuce i... 
 Printer Friendly Version
1/30/2007Meridian Bioscience Announces Final Redemption of its 5% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has called for redemption on March 1, 2007, all of its outstanding 5% Convertible Subordinated Debentures due September 1, 2013, at a 1% call premium plus accrued interest. At January 29, 2007, there were approximately $1.5 million of principal amount of such debentures outstanding. On or prior to the close of business on February 27, 2007, holders of the ... 
 Printer Friendly Version
1/18/2007Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2007 Guidance
GENERAL HIGHLIGHTS CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record first quarter net sales of $28,720,000, a 15% increase over the same period of the prior fiscal year; -- reported record quarterly net earnings of $5,564,000, a 40% increase over the same period of the prior fiscal year; -- reported record first quarter diluted per share earnings of $0.21,... 
 Printer Friendly Version
1/4/2007Meridian Bioscience Completes Production of Clinical Respiratory Syncytial Virus (RSV) for Human Clinical Trials
CINCINNATI--(BUSINESS WIRE)--Jan. 4, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS), formerly Viral Antigens, Inc., completed manufacturing of a clinical infectious inoculum of respiratory syncytial virus (RSV) in its biopharmaceutical facility located in Memphis, TN. The RSV clinical material will be used by a contract biopharmaceutical client to conduct human challenge studies in ord... 
 Printer Friendly Version
11/15/2006Meridian Bioscience Reports Record Fiscal 2006 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 15, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported record fiscal 2006 net sales of $108.4 million and record diluted earnings per share of $0.68, respective increases of 17% and 31% over the prior fiscal year; reported record fourth quarter fiscal 2006 net sales of $28.7 million and diluted earnings per share of $0.18, respecti... 
 Printer Friendly Version
10/25/2006Meridian Licenses Molecular Test Technology from Eiken Chemical Co., Ltd.
CINCINNATI--(BUSINESS WIRE)--Oct. 25, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) announced that it has completed a license agreement with Eiken Chemical Co., Ltd., Japan, for its "LAMP" (Loop-mediated Isothermal Amplification) technology. The LAMP technology is a cutting-edge nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single temperature. Unlike other amplification methods, no specialized equipment is necessary to perform ... 
 Printer Friendly Version
10/17/2006Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 17, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the fourth year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consistent pattern of po... 
 Printer Friendly Version
9/21/2006Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 21, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Sciences Conference, Tuesday, September 26, 2006 at 1:30 p.m. ET at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present. A question and answer session will follow and some of the information provided during the session may not have been... 
 Printer Friendly Version
8/14/2006Meridian Partners with Merck KGaA/Germany to Develop New Products
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has entered into a partnership agreement with the Performance & Life Science Chemicals Division of Merck KGaA, Darmstadt, Germany and its American company EMD. This strategic partnership is focused on the development of new assays for the clinical market, which Meridian will sell through its established, best-in-class sales force and distribution partners. This... 
 Printer Friendly Version
8/9/2006Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2007 and Reaffirms Fiscal 2006 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 9, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2007 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2007, management expects net sales to be in the range of $118 to $123 million and per share diluted earnings to be between $0.83 and $0.87. The per share estimates assume an incre... 
 Printer Friendly Version
7/20/2006Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2006 Guidance, and Comments on Fiscal 2007 Outlook
CINCINNATI--(BUSINESS WIRE)--July 20, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record third quarter and nine-month sales of $26,583,000 and $79,763,000, respectively, an increase of 5% and 17% over the same periods of the prior fiscal year; reported record third quarter and nine-month operating income of $6,893,000 and $20,040,000, respectively, an increase of 21% and 39% over the same periods of the prior ... 
 Printer Friendly Version
7/6/2006Meridian Bioscience Announces Its Inclusion in the New NASDAQ Global Select Market - The Market With the Highest Initial Listing Standards in the World -
CINCINNATI, Jul 06, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it is included in the new NASDAQ Global Select Market. The NASDAQ Global Select Market has the highest initial listing standards of any exchange in the world based on financial and liquidity requirements. Prior to the change, the company had been listed on the NASDAQ National Market. Beginning July 3, NASDAQ-listed companies will be classified under three listing ti... 
 Printer Friendly Version
6/26/2006FORTUNE Small Business Ranks America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--June 26, 2006--FORTUNE Small Business announced today that Meridian Bioscience, Inc. (NASDAQ:VIVO) has been ranked 66 on the sixth annual FSB 100 list of the fastest growing small companies in America. The list, which is comprised of public companies, appears in the July/August issue of FORTUNE Small Business and is available at FSB.com. John A. Kraeutler, President and Chief Operating Officer, stated, "We would like to thank FORTUNE Small Business for... 
 Printer Friendly Version
6/15/2006Meridian Bioscience to Present at the InvesTristate Regional Public Company Investment Conference
CINCINNATI--(BUSINESS WIRE)--June 15, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the InvesTristate Regional Public Company Investment Conference on Tuesday, June 20, 2006 at 10:55 a.m. ET at the Hyatt Regency, Cincinnati, Ohio. Jack Kraeutler, President and Chief Operating Officer and Melissa Lueke, Vice President and Chief Financial Officer, are scheduled to present. A question and answer session wil... 
 Printer Friendly Version
6/12/2006Meridian Bioscience Receives FDA CLIA Waiver Status for Stomach Ulcer Test
CINCINNATI--(BUSINESS WIRE)--June 12, 2006--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received CLIA waiver status from the U.S. Food and Drug Administration (FDA) for its ImmunoCard STAT!(R) HpSA test, a rapid single-use test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this... 
 Printer Friendly Version
5/5/2006Meridian Bioscience to Present at the Robert W. Baird 2006 Growth Stock Conference
CINCINNATI, May 05, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2006 Growth Stock Conference on Tuesday, May 9, 2006 at 12:40 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow and some of the inform... 
 Printer Friendly Version
5/3/2006Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI--(BUSINESS WIRE)--May 3, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2006. This index is made up of just 3% of U.S. publicly traded companies with the most consistent records of annual dividend increases. Quoting from Mergent's correspondence, "This designation means that you (Meridian Bioscience, Inc.) are part of an elite class of companies that have successfully d... 
 Printer Friendly Version
4/20/2006Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Increases Fiscal 2006 Guidance, and Declares Regular Cash Dividend General Highlights
CINCINNATI, Ohio--(BUSINESS WIRE)--April 20, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record second quarter and six months net sales of $28,272,000 and $53,180,000, respectively, an increase of 19% and 25% over the same periods of the prior fiscal year; reported record second quarter and six months net earnings of $4,723,000 and $8,685,000, respectively, an increase of 48% and 64% over the same periods of t... 
 Printer Friendly Version
4/12/2006Meridian Bioscience Helicobacter Pylori Patent Validated by Settlement Agreement With Astra S.r.l.
CINCINNATI--(BUSINESS WIRE)--April 12, 2006--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has executed a settlement agreement with Astra S.r.l. regarding Meridian's patented technology for detecting H. pylori, the primary cause of peptic ulcers. In the agreement, Astra acknowledges the existence, validity and scope of Meridian's patent, EPO 0806667. Astra further agrees to: 1) cease all promotion and distribution of its infringing products, and; 2)... 
 Printer Friendly Version
3/16/2006Meridian Bioscience Receives FDA Clearance for New Stomach Ulcer Test
CINCINNATI--(BUSINESS WIRE)--March 16, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Premier Platinum HpSA(R) Plus, an improved new test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this disease... 
 Printer Friendly Version
2/24/2006Meridian Bioscience Named Founding Member to New NASDAQ Dividend Achievers Index
CINCINNATI--(BUSINESS WIRE)--Feb. 24, 2006--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has been included in the new NASDAQ Dividend Achievers Index as a founding member. Quoting, in part, from the February 22, 2006 press release of the NASDAQ Stock Market, Inc. The NASDAQ Dividend Achievers Index is designed to track the performance of U.S. companies that are listed on NASDAQ and meet Dividend Achievers requirements of increased annual regular ... 
 Printer Friendly Version
1/19/2006Meridian Bioscience Reports Record First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2006 Guidance
CINCINNATI, Jan 19, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio today: reported record first quarter net sales of $24,908,000, a 32% increase over the same period of the prior fiscal year; reported record first quarter net earnings of $3,962,000, an 88% increase over the same period of the prior fiscal year; reported record first quarter diluted per share earnings of ... 
 Printer Friendly Version
11/10/2005Meridian Bioscience Reports Record Fiscal 2005 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI, Nov 10, 2005 (BUSINESS WIRE) -- GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record fiscal 2005 net sales of $93 million and record diluted earnings per share of $0.52, respective increases of 17% and 30% over the prior fiscal year; reported fourth quarter fiscal 2005 net sales of $25 million and diluted earnings per share of $0.15, respective increases of 12% and 15% over the same period ... 
 Printer Friendly Version
10/31/2005Meridian Bioscience Again Recognized by Forbes as One of The 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 31, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the third year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consist... 
 Printer Friendly Version
10/18/2005Meridian Bioscience H. Pylori Patent Upheld by European Patent Office
CINCINNATI--(BUSINESS WIRE)--Oct. 18, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its patent entitled "Immunoassay for Helicobacter pylori in Fecal Specimens" has been confirmed as valid by the European Patent Office. The validity of the Patent had been challenged in four Oppositions filed by a total of seven parties. The objections raised were that the Patent added subject matter to the Application as originally filed, lacked novelty, lacked inventive steps an... 
 Printer Friendly Version
9/23/2005Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2005--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Sciences Conference, Tuesday, September 27, 2005 at 12:00 p.m. ET at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present. A question and answer session will follow and some of the information provided during the session may not have bee... 
 Printer Friendly Version
9/16/2005Meridian Bioscience Announces Pricing of $58 Million Common Stock Offering
CINCINNATI, Sep 16, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has priced a public offering of 3,300,000 shares of common stock at $17.50 per share. Of the total number of shares, 1,800,000 shares are being offered by the Company, and 1,500,000 shares are being offered by The William J. Motto Irrevocable Family Trust. Mr. Motto is the Company's Chairman and Chief Executive Officer. The shares are being offered pursuant to a sh... 
 Printer Friendly Version
8/15/2005Meridian Bioscience Announces 3-for-2 Stock Split and Provides Sales and Earnings Guidance for Fiscal 2006
CINCINNATI--(BUSINESS WIRE)--Aug. 15, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its Board of Directors has declared a three-for-two stock split of the Company's common shares. The record date is August 29, 2005 with the payment date set for September 2, 2005. Cash will be paid in lieu of fractional shares. Management also today provided the financial community with guidance regarding the Company's fiscal 2006 sales and earnings estimates. ... 
 Printer Friendly Version
7/21/2005Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Higher Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--July 21, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record third quarter sales of $25,421,000, a 39% increase over the same period of the prior fiscal year and an all-time record for any quarter in the Company's history; reported record third quarter operating income of $5,708,000, an increase of 70% over the same period of the prior fiscal year and an all-time record for any qu... 
 Printer Friendly Version
7/11/2005Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--July 11, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2005 earnings from a range of $0.66 to $0.70 per share to a new range of $0.73 to $0.76 per share. The per share estimates assume an increase in average shares outstanding from approximately 15.3 million at fiscal 2004 year end to 16.1 million at fiscal 2005 year end. Due to stronger than expected third quarter shipments, net sales guidance... 
 Printer Friendly Version
7/7/2005Meridian Bioscience Awarded Exclusive, Global License for Parvovirus B19 Vaccine from the National Institutes of Health
CINCINNATI, Jul 07, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), Memphis, TN, was awarded the exclusive global license for the recombinant Parvovirus B19 Vaccine technology from the National Institutes of Health (NIH). The license provides VAI with the exclusive and global rights to utilize the NIH's patented technology to develop, manufacture, and market the Parvovirus B19 vaccine. Previo... 
 Printer Friendly Version
7/6/2005Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)
CINCINNATI, Jul 06, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2005. This index is made up of 314 stocks composed of U.S. companies with the most consistent records of annual dividend increases. Quoting from Mergent's press release, "Dividend Achievers represent the elite of the U.S. stock market. These are generally well known companies that as a group have been... 
 Printer Friendly Version
6/22/2005New Meridian Bioscience Patent Improves Rubella Testing Accuracy
CINCINNATI--(BUSINESS WIRE)--June 22, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that Viral Antigens, Inc. (VAI), a wholly owned life science subsidiary, received a patent entitled "Specificity in the Detection of Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark Office. This patent encompasses improved methods for detection of anti-rubella IgM antibodies in commercial diagnostic products, utilized to test blood samples for the presence o... 
 Printer Friendly Version
6/20/2005Fortune Small Business Ranks Meridian Bioscience Among America's Fastest-Growing Small Companies
CINCINNATI--(BUSINESS WIRE)--June 20, 2005--(NASDAQ:VIVO) - FORTUNE Small Business announced today that Meridian Bioscience, Inc., has been ranked 80 on the fifth annual FSB 100 list of the 100 fastest growing small companies in America. The list, which is comprised of public companies, appears in the July/August issue of FORTUNE Small Business, available on newsstands July 4 and at www.fsb.com. John A. Kraeutler, President and Chief Operating Officer, stated, "This recognition by F... 
 Printer Friendly Version
6/14/2005Meridian Bioscience Announces Final Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI, Jun 14, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has called for redemption on July 8, 2005, all of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. At June 10, 2005, there were approximately $1.8 million of principal amount of such debentures outstanding. On or prior to the close of business on July 7, 2005, holders of the 7% Convertible Debentures be... 
 Printer Friendly Version
6/1/2005Meridian Bioscience Recognized as One of the 100 Best Small Companies of 2005 by Business Week Magazine
CINCINNATI--(BUSINESS WIRE)--June 1, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been recognized by Business Week magazine as one of "The 100 Best Small Companies." The 100 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $50 million and $1.5 billion. Additional qualification criteria included rankings based upon sales... 
 Printer Friendly Version
5/10/2005Meridian Bioscience to Present at the Robert W. Baird 2005 Growth Stock Conference
CINCINNATI--(BUSINESS WIRE)--May 10, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2005 Growth Stock Conference on Wednesday, May 11, 2005 at 2:05 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow and some of the infor... 
 Printer Friendly Version
5/9/2005Meridian Bioscience Announces Third Partial Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--May 9, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has called for redemption on June 3, 2005, $2.5 million in principal amount of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. The called 7% Convertible Debentures will be selected in accordance with the applicable procedures of the Trustee, U.S. Bank, National Association, for partial redemption. Holders of 7% Convertible D... 
 Printer Friendly Version
4/21/2005Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--April 21, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported all-time record quarterly sales of $23,686,000, a 13% increase over the same period of the prior fiscal year and an all-time record for any quarter in the Company's history; reported all-time record quarterly operating income of $5,198,000, an increase of 31% over the same period of the prior fiscal year and an all-time recor... 
 Printer Friendly Version
4/13/2005Meridian Bioscience Announces Preliminary Operating Results for the Second Quarter, Reaffirms Guidance, and Comments on Recommended Destruction of Influenza A Samples
CINCINNATI--(BUSINESS WIRE)--April 13, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that, based on preliminary results, it expects to report net sales of approximately $23.5 million and diluted earnings per share of between $0.19 and $0.20 for the quarter ended March 31, 2005. For the same period of the previous fiscal year, sales and diluted earnings per share were $20.94 million and $0.15, respectively. The Company will report its final results for the fiscal second qu... 
 Printer Friendly Version
3/16/2005Meridian Bioscience Expands Presence in Veterinary Market and Announces Agreement with Synbiotics Corporation
CINCINNATI--(BUSINESS WIRE)--March 16, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a Distribution Agreement with Synbiotics Corporation for the distribution of VAI's veterinary products through Synbiotics' global sales, marketing, and distribution channels. Synbiotics develops, manufactures, and markets veterinary diagnostic products for the animal health market and is seeking to broaden its ... 
 Printer Friendly Version
3/1/2005Meridian Bioscience to Present at Friedman, Billings, Ramsey & Co. 2005 Washington Conference
CINCINNATI, Mar 1, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Friedman, Billings, Ramsey & Co. 2005 Washington Conference on Thursday, March 3, 2005 at 2:20 p.m. EST at the Mandarin Oriental Washington in Washington, D.C. The Conference will feature presentations from companies representing Homeland Security, Defense and Government IT. Jack Kraeutler, President and Chief Operating Of... 
 Printer Friendly Version
2/9/2005Meridian Bioscience Targets Biodefense Market by Providing Contract Services for BEI Resources
CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI) has entered the emerging biodefense market by providing contract services for Biodefense and Emerging Infections (BEI) Resources. BEI Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to acquire, authenticate, and produce reage... 
 Printer Friendly Version
2/1/2005Meridian Bioscience Completes Acquisition of O.E.M. Concepts and Comments on New Growth Opportunities
CINCINNATI--(BUSINESS WIRE)--Feb. 1, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has completed the purchase of O.E.M. Concepts, Inc., highlights include: purchase price of $6.0 million in cash and a performance based earnout opportunity of $2.3 million over a four-year period, as previously reported; earnings accretion of between $0.01 and $0.02 for the balance of fiscal 2005 and $0.04 to $0.06 for fiscal 2006 ... 
 Printer Friendly Version
1/20/2005Meridian Bioscience Reports Record First Quarter Operating Results, Executes Agreement To Buy O.E.M. Concepts, Declares Higher Dividend, and Reaffirms Fiscal 2005 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 20, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record first quarter net sales of $18,842,000, a 4% increase over the same period of the prior fiscal year; reported record first quarter net earnings of $2,110,000, an 18% increase over the same period of the prior fiscal year; reported record first quarter dilu... 
 Printer Friendly Version
1/18/2005Meridian Bioscience Reports Completion of 7% Convertible Debentures Redemption
CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2005--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its call for the redemption of $4.0 million in principal amount of its outstanding 7% Convertible Subordinated Debentures Due September 1, 2006, was successfully completed on January 14, 2005, as planned. The result of the redemption call was that $3.4 million was converted into 211,000 shares of the Company's underlying common stock and $603,000 was redeemed at par v... 
 Printer Friendly Version
12/20/2004Meridian Bioscience Announces Second Partial Redemption of Its 7% Convertible Subordinated Debentures
CINCINNATI, Dec 20, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that it has called for redemption on January 14, 2005, four million dollars ($4 million) in principal amount of its outstanding 7% Convertible Subordinated Debentures due September 1, 2006, at par plus accrued interest. The called 7% Convertible Debentures will be selected in accordance with the applicable procedures of the Trustee, U.S. Bank, National Association, for partial redemption. ... 
 Printer Friendly Version
11/17/2004Meridian Bioscience Reports Record Fiscal 2004 Operating Results and Increases Regular Cash Dividend Rate for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--Nov. 17, 2004--Meridian Bioscience, Inc., (NASDAQ:VIVO) GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record fiscal 2004 net sales of $79.6 million and diluted earnings per share of $0.60, respective increases of 21% and 28% over the prior fiscal year; reported record fourth quarter fiscal 2004 net sales of $22.2 million and diluted earnings per share of $0.19... 
 Printer Friendly Version
11/15/2004Meridian Bioscience Increases Fiscal 2005 Earnings Per Share Guidance
CINCINNATI, Nov 15, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2005 earnings from a range of $0.62 to $0.66 per share to a new range of $0.66 to $0.70 per share. The per share estimates assume an increase in average shares outstanding from approximately 15.3 million at fiscal 2004 year end to 15.6 million at fiscal 2005 year end. Management continues to believe net sales will be in the range of $84 to ... 
 Printer Friendly Version
11/10/2004Meridian Signs Agreement in Principle to Acquire Leading Manufacturer and Distributor of Biological Components
CINCINNATI--(BUSINESS WIRE)--Nov. 10, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent to acquire all the outstanding capital stock of O.E.M. Concepts, Inc., a leading producer and distributor of biological components headquartered in Toms River, New Jersey. The purchase price includes cash and future performance-based earn out opportunities, the amounts of which were not disclosed. O.E.M. Concepts' management team will remain in place and ... 
 Printer Friendly Version
10/21/2004Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies
CINCINNATI--(BUSINESS WIRE)--Oct. 21, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been recognized by Forbes as one of "The 200 Best Small Companies" for the second year in a row. The 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $750 million. Additional qualification criteria included a consistent pattern of posit... 
 Printer Friendly Version
10/5/2004Meridian Bioscience Announces Award Of SBIR Grant and Submission of Proposal for Biodefense Program
CINCINNATI--(BUSINESS WIRE)--Oct. 5, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) announced today it has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). This Phase I Grant will help fund research to develop highly specific recombinant antibodies to Clostridium difficile toxins A&B and then use these unique antibodies to develop rapid, inexpensive and sensitive diagnostics. Meridian will continue to pursue additional ... 
 Printer Friendly Version
9/23/2004Meridian Bioscience to Present at UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that the Company has been invited to present at the UBS Global Life Science Conference, Wednesday, September 29, 2004 at 4:30 p.m. EDT at the Grand Hyatt New York in New York City. Jack Kraeutler, President and Chief Operating Officer, has been scheduled to present. A question and answer session will follow and some of the information provided during the session may not have been previousl... 
 Printer Friendly Version
8/26/2004Meridian Bioscience Announces FDA Clearance of New Rapid Test for Severe Colitis
CINCINNATI--(BUSINESS WIRE)--Aug. 26, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard Toxins A&B, a rapid new test for the diagnosis of a major cause of antibiotic-associated colitis. This test detects the most important toxins produced by strains of the Clostridium difficile bacterium (C. difficile). C. difficile is recognized as the major cause of colitis ... 
 Printer Friendly Version
8/3/2004Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2005
CINCINNATI--(BUSINESS WIRE)--Aug. 3, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2005 sales and earnings estimates. Based on the Company's business planning and budgeting activities, for the fiscal year ending September 30, 2005, management expects net sales to be in the range of $84 to $88 million and per share diluted earnings to be between $0.62 and $0.66. The per share estimates assume an increase i... 
 Printer Friendly Version
8/2/2004Meridian Bioscience to Present at Baird's 2004 Small Cap Conference
CINCINNATI--(BUSINESS WIRE)--Aug. 2, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at Baird's 2004 Small Cap Conference Wednesday, August 4, 2004 at 2:20 p.m. EDT at the Pierre Hotel in New York City. A question and answer session will follow and some ... 
 Printer Friendly Version
7/22/2004Meridian Bioscience Reports Record Third Quarter Sales, Higher Earnings, Declares Regular Dividend, and Reaffirms Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--July 22, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record third quarter sales of $18,256,000, a 16% increase over last year's third quarter; reported diluted earnings per share of $0.14, a 17% increase over the same period last year; declared a regular cash dividend of $0.10 per share, 11% higher than the quarterly rate of fiscal 2003; and reaffirmed its recently increased guidance of sales be... 
 Printer Friendly Version
6/29/2004Meridian Bioscience Recognized as One of Ohio's Top Exporters in 2004
CINCINNATI--(BUSINESS WIRE)--June 29, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been recognized by the Governor of the State of Ohio, the Honorable Bob Taft, as one of Ohio's top exporters in 2004. Meridian was honored with a Governor's Excellence in Exporting Award ("E" Award) in a ceremony on June 24, 2004. The Governor's "E" Award recognizes Ohio companies that have increased sales through exports, have increased Ohio-Based employment as a direct ... 
 Printer Friendly Version
6/3/2004Meridian Bioscience Enters Strategic Collaboration With Viral Therapeutics
CINCINNATI--(BUSINESS WIRE)--June 3, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a strategic collaboration with Viral Therapeutics, Inc. (VTI), Ithaca, NY, to support the clinical and commercial development needs of biopharmaceutical partners. Viral Therapeutics is an expert in the development of recombinant proteins and in production optimization. Viral Antigens' expertise i... 
 Printer Friendly Version
5/26/2004Meridian Bioscience Announces Licensing Agreement With Cincinnati Children's Research Foundation
CINCINNATI--(BUSINESS WIRE)--May 26, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has entered into a license agreement with Cincinnati Children's Research Foundation for technologies related to the detection of norovirus, the primary cause of "stomach flu". This agreement, which is comprised of both exclusive and co-exclusive provisions, encompasses products for the clinical diagnosis of noroviruses and other products arising from the technology. Noroviruse... 
 Printer Friendly Version
5/17/2004Meridian Bioscience Announces European Launch of New Rapid Test for Severe Colitis
CINCINNATI--(BUSINESS WIRE)--May 17, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has begun to sell its newest product, ImmunoCard Toxins A&B in the European market. This important new test detects toxins produced by strains of the Clostridium difficile bacterium (C. difficile). C. difficile is recognized as the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur following antibiotic therapy. In hospitals or nursing home facil... 
 Printer Friendly Version
4/22/2004Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Increases Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--April 22, 2004--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported all-time record quarterly sales of $20,940,000, a 24% increase over the same period of the prior fiscal year and all-time record for any quarter in the Company's history; reported all-time record quarter operating income of $3,981,000, an increase of 5% over the same period of the prior fiscal year and an all-time record for ... 
 Printer Friendly Version
3/18/2004Meridian Bioscience Added to Mergent's Dividend Achievers Index
CINCINNATI--(BUSINESS WIRE)--March 18, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has been added to Mergent's Dividend Achievers Index(TM) for 2004. This index is made up of 303 stocks composed of U.S. companies with the most consistent records of annual dividend increases. Quoting from Mergent's press release "Dividend Achievers(TM) are publicly listed U.S. companies that have increased regular dividends for the past 10 consecutive years or longer, and th... 
 Printer Friendly Version
2/3/2004Meridian Bioscience Granted International ISO Certification to Manufacture Medical Devices for Export
CINCINNATI--(BUSINESS WIRE)--Feb. 3, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has completed all activities required for ISO 13485 registration and final certification. ISO 13485 is a quality systems approach to managing the processes for manufacturing medical devices to ensure that they conform to customer expectations and governmental standards. More than 75 countries recognize ISO 13485 as the standard of practice for medical device manufacturing. In... 
 Printer Friendly Version
1/30/2004Meridian Bioscience Reports Completion of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2004--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its offer to exchange 5% Convertible Subordinated Debentures due 2013 for its outstanding 7% Convertible Subordinated Debentures due 2006, expired at 12:00 midnight EST on Wednesday, January 28, 2004. LaSalle Bank National Association, the exchange agent for the offer, has advised the Company that approximately $4 million in principal amount of the outstanding debentures was ten... 
 Printer Friendly Version
1/27/2004Meridian Bioscience Awarded New Rubella Patent
CINCINNATI, Jan 27, 2004 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Viral Antigens, Inc. (VAI), a wholly owned life science subsidiary, received a patent entitled "Improved Specificity in the Detection of Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark Office. This patent encompasses improved methods for detection of anti-rubella IgM antibodies in commercial diagnostic products, utilized to test blood samples for the p... 
 Printer Friendly Version
1/22/2004Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares First Quarter Higher Regular Cash Dividend, and Reaffirms Fiscal 2004 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record quarterly net sales of $18,166,000, a 13% increase over the same period of the prior fiscal year and an all time record for any quarter in the Company's history; reported diluted net earnings of $1,795,000 or $0.12 per diluted share, a 26% increase over the same period of the prior fiscal year; reported record first quarter oper... 
 Printer Friendly Version
1/13/2004Meridian Bioscience to Begin Redeeming 7% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--Jan. 13, 2004--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it will begin a program to redeem at par its outstanding issue of 7% Convertible Subordinated Debentures due 2006. The first call for redemption, in the amount of $4 million, will take place soon after January 28, 2004, the date when debentureholders lose their right to exchange their current debentures for new debentures. It is anticipated that the Company will make additional redempt... 
 Printer Friendly Version
1/12/2004Meridian Bioscience Hires Vice President of Sales and Marketing
CINCINNATI--(BUSINESS WIRE)--Jan. 12, 2004--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that Gregory S. Ballish has joined Meridian Bioscience, Inc. as Vice President Sales and Marketing. Ballish joins Meridian as a pharmaceutical and diagnostics industry veteran, having spent the last five years in senior sales management and strategic customer marketing roles with Janssen Pharmaceutica (Johnson & Johnson subsidiary). Mr. Ballish has also held positions of national sales and... 
 Printer Friendly Version
12/23/2003Meridian Bioscience Extends Expiration Date of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Dec. 23, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it is extending the expiration date for its offer to exchange 5% Convertible Subordinated Debentures due 2013 (New Debentures) in the principal amount of $16,000,000 for an equal amount of outstanding 7% Convertible Subordinated Debentures due 2006 (Existing Debentures), and related withdrawal rights, until 12:00 midnight EST on Wednesday, January 28, 2004, unless extended or earlier t... 
 Printer Friendly Version
12/12/2003Meridian Bioscience Extends Expiration Date of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Dec. 12, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it is extending the expiration date for its offer to exchange 5% Convertible Subordinated Debentures due 2013 (New Debentures) in the principal amount of $16,000,000 for an equal amount of outstanding 7% Convertible Subordinated Debentures due 2006 (Existing Debentures), and related withdrawal rights, until 12:00 midnight EST on Tuesday, December 30, 2003, unless extended or earlier t... 
 Printer Friendly Version
12/11/2003Meridian Bioscience Launches New Flu Test for Physician Offices
CINCINNATI--(BUSINESS WIRE)--Dec. 11, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has begun marketing a new physician's office Influenza A&B Test. This rapid test is simple enough to be performed in physicians' offices and small labs. The new product expands Meridian's influenza and RSV testing lines that continue to be in high demand and have been sold to hospital labs for the past two years. This rapid physician's office flu test differentiates between the A an... 
 Printer Friendly Version
12/9/2003Meridian Bioscience Announces New Rapid Test for Stomach Ulcers
CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!(R) HpSA, a rapid new test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this patho... 
 Printer Friendly Version
11/25/2003Meridian Bioscience to Present at Friedman Billings Ramsey 10th Annual Investor Conference
CINCINNATI--(BUSINESS WIRE)--Nov. 25, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at the Friedman Billings Ramsey 10th Annual Investor Conference on Tuesday, December 2, 2003 at 9:30 a.m. ET at the Sheraton New York Hotel & Towers in New York City. A... 
 Printer Friendly Version
11/18/2003Meridian Bioscience Reports Fiscal 2003 Year End and Fourth Quarter Operating Results, Declares Regular Quarterly Cash Dividend, Discusses Fiscal 2004 Dividends and Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 18, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported record fiscal 2003 net sales of $65.9 million (up 11% over fiscal 2002) and diluted earnings per share of $0.47 (up 38% over fiscal 2002) and at the upper range of management's guidance; reported record fourth quarter fiscal 2003 net sales of $17.2 million (up... 
 Printer Friendly Version
11/12/2003Meridian Bioscience Announces Exchange Offer for and Plans to Redeem 7% Convertible Subordinated Debentures Due 2006
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has commenced an offer to exchange $16.0 million principal amount of new Convertible Subordinated Debentures due 2013 for an equal principal amount of its outstanding 7% Convertible Subordinated Debentures due 2006. The new debentures will bear interest at 5% per year, payable semi-annually each March 1 and September 1. The principal amount of the new debentures wi... 
 Printer Friendly Version
10/15/2003Meridian Bioscience Recognized as One of Forbes' 200 Best Growth Companies in America
CINCINNATI--(BUSINESS WIRE)--Oct. 15, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Forbes has recognized it as one of the "200 Best Growth Companies in America", as reported in their October 27, 2003 edition. The Forbes 200 Best Growth Companies in America list is selected from a database of 3,500 candidates whose last 12-month sales range between $5 million and $600 million. Additional qualification criteria included profitability tests and l... 
 Printer Friendly Version
10/6/2003Meridian Bioscience Awarded Contract to Manufacture Parvovirus Vaccine for National Institutes of Health - NIH
CINCINNATI--(BUSINESS WIRE)--Oct. 6, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been awarded a contract to manufacture clinical grade recombinant protein Parvovirus B19 vaccine for The National Institutes of Health. Vaccine production will take place at the Company's life science manufacturing facility located at Viral Antigens, Inc. (VAI), Memphis, TN, a wholly owned subsidiary. Under the terms of this contract, National Heart, Lung, and B... 
 Printer Friendly Version
9/26/2003Meridian Bioscience Files Shelf Registration Statement
CINCINNATI--(BUSINESS WIRE)--Sept. 26, 2003--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission registering an aggregate of $60 million of securities, which includes common stock, preferred stock, debt or other types of securities. The Company stated that it believes this universal shelf registration statement will facilitate its ability to finance its growth strategies through the ... 
 Printer Friendly Version
7/31/2003Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2004
CINCINNATI--(BUSINESS WIRE)--July 31, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2004 sales and earnings estimates. Based on the Company's business planning and budgeting activities, for the fiscal year ending September 30, 2004, management expects net sales to be in the range of $71 to $75 million and per share diluted earnings to be between $0.47 and $0.53. The per share estimates assume an increase i... 
 Printer Friendly Version
7/30/2003Meridian Bioscience to Present at Robert W. Baird & Co.'s 2003 Small Cap Conference
CINCINNATI--(BUSINESS WIRE)--July 30, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at the Robert W. Baird 2003 Small Cap Conference Tuesday, August 5, 2003 at 10:45 a.m. EDT at the Four Seasons Hotel in New York City. A question and answer session wil... 
 Printer Friendly Version
7/24/2003Meridian Bioscience Reports Third Quarter Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
CINCINNATI--(BUSINESS WIRE)--July 24, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record third quarter sales of $15,693,000, a 5% increase over the same period of the prior fiscal year; reported diluted earnings per share of $0.12, a 9% increase over the same period of the prior fiscal year; reported third quarter operating income of $3,068,000, second highest third quarter earnings in ... 
 Printer Friendly Version
7/21/2003Meridian to Manufacture and Distribute Chagas' Disease Proteins Under License Agreement with Corixa Corporation
CINCINNATI--(BUSINESS WIRE)--July 21, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it will begin production of recombinant Trypanosoma cruzi (Chagas' disease) antigen under a license agreement with Corixa Corporation (Nasdaq:CRXA) in its life science production laboratories located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers for use i... 
 Printer Friendly Version
7/1/2003Meridian Bioscience Added to Russell 2000 Index
CINCINNATI--(BUSINESS WIRE)--July 1, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been added to the Russell 2000(R) Index of small-capitalization stocks. The Russell Indexes were jointly developed by the Frank Russell Company and the New York Futures Exchange to represent investment-grade equities. Meridian's inclusion in the Russell Index is a result of the Frank Russell Company's annual assessment and reconstitution of its U.S. equity indexes. Final a... 
 Printer Friendly Version
6/10/2003Meridian Announces Manufacturing Agreement with Hawaii Biotech, Inc. to Produce Vaccine for Dengue Fever
CINCINNATI--(BUSINESS WIRE)--June 10, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced the signing of its second biopharmaceutical manufacturing agreement for the Company's life science production facility located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly-owned subsidiary. Hawaii Biotech, Inc. has selected VAI to manufacture and supply bulk polyvalent recombinant subunit vaccine for dengue virus 1-4. The bulk vaccine for human clinical studies will be produced in ... 
 Printer Friendly Version
4/24/2003Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
CINCINNATI--(BUSINESS WIRE)--April 24, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported all-time record quarterly sales of $16,913,000, a 12% increase over the same period of the prior fiscal year; reported diluted earnings per share of $0.13, a 30% increase over the same period of the prior fiscal year; reported all-time record quarterly operating income of $3,784,000; declared a regular cash dividend of $... 
 Printer Friendly Version
4/9/2003Meridian Announces First Manufacturing Agreement for Its New Life Science Production Facility and Names Richard Eberly Head of Newly Established Life Science Business Unit
CINCINNATI--(BUSINESS WIRE)--April 9, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has signed its first manufacturing agreement for the Company's new cGMP life science production facility located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly owned subsidiary. Under the terms of the agreement, VAI will optimize manufacturing processes and produce a specific insect cell-derived recombinant protein for its contract partner. This recombinant protein will be VA... 
 Printer Friendly Version
3/24/2003Japanese Multicenter Study of Meridian HpSA -- Stomach Ulcers -- Test Supports Usefulness in Diagnosing Pediatric Infections
CINCINNATI, Mar 24, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced the publication, in The American Journal of Gastroenterology, of an important multicenter clinical study of Meridian's Premier Platinum HpSA(R) Test (HpSA) conducted in leading childrens' hospitals in Japan. The study, performed by the Japanese Pediatric HpSA Study Group, was designed to evaluate the diagnostic accuracy of Meridian's HpSA test in Japanese children. Based upon the results of... 
 Printer Friendly Version
2/19/2003Dr. K. John Morrow, Jr., Noted Geneticist and Molecular Biologist, Joins Meridian Bioscience, Inc.
CINCINNATI, Feb 19, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Dr. K. John Morrow, Jr. has joined its expanding scientific team. Prior to Meridian, Dr. Morrow was Professor of Cell Biology and Biochemistry at Texas Tech University Health Sciences Center in Lubbock, Texas. Dr. Morrow's research expertise is in the field of genetics and molecular systems for immunology. His current research is in the area of genetically engineered a... 
 Printer Friendly Version
1/21/2003Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares Higher Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Jan. 21, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today: reported record quarterly net sales of $16,103,000 resulting in net earnings of $1,424,000 ($0.10 per diluted share) for the first quarter ended December 31, 2002: net sales were an all time record for any quarter in the Company's history; declared a regular quarterly cash dividend of $0.09 per share, $0.02 per share higher (+29%) tha... 
 Printer Friendly Version
1/15/2003Meridian Awarded New Patent for Novel Transport Device
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has received from the U.S. Patent and Trademark Office the official Notice of Allowance for a patent entitled "Biological Sampling and Storage Container Utilizing a Desiccant". The patent relates to a device for the sampling and storing of specific biological samples used in medical testing. This allowance compliments a patent that was granted earlier (Patent No. 6,29... 
 Printer Friendly Version
1/9/2003Meridian's E. Coli Toxin Test Granted New Claim
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Jan. 9, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been granted FDA clearance to market an additional claim related to its ImmunoCard STAT!(R) E. coli 0157 Plus. This test identifies the most dangerous Shiga toxin-producing E. coli bacteria that can cause severe kidney damage or death, especially in infected children under 5 years of age. This new claim will enable the toxin-pro... 
 Printer Friendly Version
11/19/2002Meridian Bioscience Announces Dividend Actions and Provides Guidance for Fiscal 2003
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 19, 2002--Meridian Bioscience, Inc., (Nasdaq:VIVO) today (i) declared the regular cash dividend for the fourth quarter ended September 30, 2002, (ii) increased the regular cash dividend rate for fiscal 2003, and adopted a new cash dividend policy; and (iii) provided guidance to the financial community with respect to its operating projections for the current fiscal year ending September 30, 2003 as follows: Fisca... 
 Printer Friendly Version
11/13/2002Meridian Bioscience Reports Fiscal 2002 Year End and Fourth Quarter Operating Results
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 13, 2002--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results for the fourth quarter and fiscal year ended September 30, 2002. Fiscal Year 2002 Net sales for fiscal 2002 were $59,104,000 as compared to $56,527,000 for fiscal 2001, an increase of $2,577,000 or 4.6%. Net income for fiscal 2002 was $5,031,000, $0.34 per diluted share, compared to a loss of $10,275,0... 
 Printer Friendly Version
11/8/2002Meridian Bioscience and Biotrin Holdings Terminate Acquisition Talks
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2002--Meridian Bioscience, Inc.,(Nasdaq:VIVO) today announced that it and Biotrin Holdings plc have terminated negotiations and ceased further discussions regarding Meridian Bioscience's earlier interest in acquiring Biotrin Holdings. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related pr... 
 Printer Friendly Version
10/7/2002Meridian Reports on Biotrin Progress
CINCINNATI, Oct 7, 2002 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced it is continuing its pre-acquisition due diligence review of Biotrin Holdings plc, an Irish-based diagnostics company, and is concurrently in the process of negotiating a definitive stock purchase agreement. Although there can be no assurances that this previously announced contemplated acquisition will take place, progress is being made and it is anticipated that the purchase of Biotrin will... 
 Printer Friendly Version
7/23/2002Meridian Reports Profitable Third Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects
CINCINNATI, Jul 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) EPS of $0.11 reported for the third quarter of fiscal year 2002 compared to ($0.04) in the prior year period EPS of $0.28 reported for the first nine months of fiscal year 2002 compared to ($0.72) in the prior year period Fiscal year 2002 EPS estimate of $0.38 to $0.43 reaffirmed Strong EBITDA and positive cash flow in fiscal year 2002 Bi... 
 Printer Friendly Version
7/22/2002Meridian Commences Distribution of New Rapid Test for Stomach Ulcers
CINCINNATI, Jul 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has begun international distribution of its patent protected ImmunoCard Stat! HpSA rapid test for Helicobacter pylori bacteria, the primary cause of stomach ulcers. The ImmunoCard STAT! HpSA test is highly accurate, simple to perform, and yields results in just five minutes. The speed and simplicity of the test makes it ideal for use in quickly diagnosing, treating and monitoring su... 
 Printer Friendly Version
7/18/2002Meridian Announces Japanese Market Launch of Rapid Adenovirus Test
CINCINNATI, Jul 18, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its Japanese distributor, TFB, Inc. of Tokyo, Japan has begun distribution of Meridian's ImmunoCard STAT!(R) Adenovirus test, having received approval to market by the Japanese Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid point-of-care test that can be used in a physician's office to directly detect the virus that can cause conjunctivitis, pharyngitis, or... 
 Printer Friendly Version
5/23/2002Meridian Signs Agreement in Principle to Acquire Biotrin Holdings plc
CINCINNATI--(BW HealthWire)--May 23, 2002--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent to acquire all the outstanding capital stock of Biotrin Holdings plc, headquartered in Dublin, Ireland. The purchase price includes cash and possible future earnout opportunities, the amounts of which were not disclosed. The transaction is expected to be completed within 45 days. Biotrin develops, manufactures and sells lead... 
 Printer Friendly Version
5/14/2002Meridian Appoints PricewaterhouseCoopers LLP as Its Independent Public Accountants
CINCINNATI, May 14, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has appointed PricewaterhouseCoopers LLP as the Company's Independent Certified Public Accountants for fiscal year 2002. This appointment is the culmination of an extensive two-month evaluation and selection process involving the Audit Committee of the Board of Directors and executive management. William J. Motto, Chairman and Chief Executive Officer, stated, "We believe the Pric... 
 Printer Friendly Version
4/23/2002Meridian Reports Profitable Second Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects
CINCINNATI, Apr 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO): Second quarter EPS of $0.10 reported First half EPS of $0.18 reported Full year EPS of $0.38 to $0.43 reaffirmed Record EPS for fiscal 2003 expected Strong EBITDA and positive cash flow Fully funded internal business plan Solid financial condition No impairment charges under SFAS 142 Life science progress Acquisition search underw... 
 Printer Friendly Version
3/28/2002Meridian's Patented Premier HpSA Stomach Ulcer Test Subject of Article in Annals of Internal Medicine
CINCINNATI, Mar 28, 2002 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that an important drug eradication study of its Premier HpSA(R) (stomach ulcer) test has been published in an article entitled, "The Stool Antigen Test for Detection of Helicobactor pylori after Eradication Therapy," (Dr. D. Vaira, Dr. N. Vakil, et al.). Appearing in the February 19, 2002, issue of the Annals of Internal Medicine, the article reports on a study designed to determine wheth... 
 Printer Friendly Version
1/22/2002Meridian Bioscience Reports Favorable First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms EPS Guidance for Fiscal 2002
CINCINNATI, Jan 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced net earnings of $1,187,000, or $0.08 per fully diluted share for the first quarter ended December 31, 2001. This compares with a net loss of $8,192,000, or $0.56 per share for the same period of the prior fiscal year. Net sales for the first quarter of this fiscal year were $13.6 million compared to $15.3 million for the first quarter of the prior fiscal year, a decline of approximately ... 
 Printer Friendly Version
1/9/2002Meridian Bioscience's Helicobacter pylori -- Stomach Ulcers -- Technology Granted European Patent
CINCINNATI, Jan 9, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been granted a patent in Europe covering its innovative technology for detecting the primary causative agent for stomach ulcers, Helicobacter pylori. This technology, which is the basis for the Premier Platinum HpSA(TM) test, was granted the first of its United States' patents in February 1998. Premier Platinum HpSA was the first noninvasive direct test for Helicobacter pylor... 
 Printer Friendly Version
1/7/2002Meridian Announces April 2002 Availability of Its Biopharmaceutical Production Facilities
CINCINNATI, Jan 7, 2002 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO), today announced that its wholly-owned subsidiary Viral Antigens, Inc. (VAI), has initiated a marketing campaign, based upon direct mail, personal contacts and an upgraded website (www.viralantigens.com), designed to communicate the anticipated availability of its new biopharmaceutical production laboratories. The Memphis, Tenn.-based VAI is combining 20 years of cell culture expertise with... 
 Printer Friendly Version
12/17/2001Meridian Bioscience Reaffirms Sales and Earnings Guidance and Provides Other Information
CINCINNATI--(BW HealthWire)--Dec. 17, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) This fiscal year earnings guidance of $0.38 to $0.43 per share, fully diluted First quarter earnings guidance of $0.07 to $0.08 per share, fully diluted Viral Antigens expansion - capital expenditure - key growth strategy Fully funded business plan - sound balance sheet - positive cash flow Cash dividend rate recently i... 
 Printer Friendly Version
11/20/2001Meridian Bioscience Expands Product Introduction to the Japanese Healthcare Market
CINCINNATI--(BW HealthWire)--Nov. 20, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its Japanese distributor, TFB, Inc. of Tokyo, Japan, filed a request to market Meridian's ImmunoCard STAT!(R)Adenovirus test with the Japanese Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid point-of-care test for direct detection of the virus that can cause conjunctivitis, pharyngitis, or gastrointestinal disease. The test is simple to perform and pr... 
 Printer Friendly Version
11/14/2001Meridian Bioscience Declares Regular Cash Dividend, Increases Regular Cash Dividend Rate and Reaffirms Sales and Earnings Guidance for Fiscal 2002
CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today (i) declared the regular cash dividend for the fourth quarter ended September 30, 2001; (ii) increased the regular cash dividend rate for fiscal 2002; and reaffirmed sales and earnings per share guidance for fiscal 2002, as follows: Fiscal 2001 Fourth Quarter Regular Cash Dividend The Board of Directors declared the regular quarterly cash dividend of $0.065 per share for the fourth qua... 
 Printer Friendly Version
11/14/2001Meridian Reports Fiscal 2001 Year End and Profitable Fourth Quarter Operating Results
CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today reported operating results for the fourth quarter and for the fiscal year ended September 30, 2001. Fourth Quarter Operating Results Net earnings for the fourth fiscal quarter ended September 30, 2001, were $171,000, or $0.01 per share. Net sales for the fourth fiscal quarter were $13,501,000 compared to $13,850,000 for the same period of the prior fiscal year, a decrease of $349,000 or... 
 Printer Friendly Version
11/8/2001Meridian Announces Agreements With Thermo Electron Corporation for the Immediate Distribution of Infectious Disease Tests for Influenza, C. difficile, E. coli and Rotavirus
CINCINNATI, Nov 8, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has signed two agreements for the distribution of important infectious disease tests with Thermo Electron Corporation (NYSE:TMO) Under the terms of the agreements, Meridian will immediately begin marketing Thermo Electron's new point-of-care tests for influenza and C. difficile in the U.S. These test kits utilize Thermo Electron's Thermo Biostar proprietary Optic... 
 Printer Friendly Version
10/22/2001Meridian Announces Distribution Agreement With ScheBo Biotech AG for the Distribution in Italy of a Novel Test for Pancreatic Dysfunction
CINCINNATI, Oct 22, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it's subsidiary Meridian Bioscience Europe Srl., has signed a Distribution Agreement with ScheBo(R)Biotech AG, a fast growing German biotechnology company, to market ScheBo Pancreatic Elastase-1 Stool Test, a non-invasive, novel test for the detection and quantification of human pancreatic elastase-1. Pancreatic Elastase-1 is an indicator of pancreatic exocrine insufficiency, which... 
 Printer Friendly Version
10/9/2001Meridian Bioscience Provides Guidance for Fiscal 2002 and Reports On Capital Adequacy and Other Matters
CINCINNATI--(BW HealthWire)--Oct. 9, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today provided guidance to the financial community with respect to its operating projections for the current fiscal year ending September 30, 2002. Based on Meridian's recently completed business planning and budgeting activities, management expects net sales to be in the range of $62 -- $65 million and fully diluted earnings per share of between $0.38 and $0.43 for fiscal 2002. ... 
 Printer Friendly Version
8/16/2001Broadlane Awards Contract to Meridian Bioscience
CINCINNATI, Aug 16, 2001 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced it has been awarded a three-year contract from Broadlane Inc., a leader in delivering supply chain services to the healthcare industry. The contract includes Meridian's full line of parasitological transport devices and several of its microbiological diagnostic products used in the detection of gastrointestinal, bacterial, and parasitic infections. Meridian's newest product for the detec... 
 Printer Friendly Version
7/24/2001Meridian Reports Profitable Third Quarter Operating Results and Declares Regular Cash Dividend
CINCINNATI--(BW HealthWire)--July 24, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results for the third quarter and for the nine months ended June 30, 2001 and declared the regular cash dividend, as follows: Third Quarter Operating Results Net sales for the third fiscal quarter ended June 30, 2001, were $13,906,000 as compared to $14,340,000 for the same period of the prior fiscal year, a decrease of $434,000 or 3%. Ex... 
 Printer Friendly Version
6/7/2001Meridian Announces First Preview of UPlink Technology At 2001 American Society of Microbiology Meeting
CINCINNATI, Jun 7, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that its highly sensitive, novel UPlink(TM) technology was previewed in a poster session at the 2001 American Society for Microbiology Conference, held in Orlando, FL. Meridian and its partner, OraSure Technologies, Inc., demonstrated, for the first time, the unique abilities of the phosphor-based UPlink technology in the detection of infectious disease. Meridian and OraSure have an exclu... 
 Printer Friendly Version
5/29/2001Meridian Bioscience Hires Vice President of Regulatory Affairs and Quality Systems
CINCINNATI--(BW HealthWire)--May 29, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has hired Susan Rolih as its Vice President of Regulatory Affairs and Quality Systems. Most recently, Ms. Rolih was Corporate Vice President - Regulatory Affairs and Quality Assurance at Immucor, Inc., Norcross, GA. She previously held titles of Vice President-Regulatory Affairs and Quality Assurance and Vice President-Technical Services. Ms. Rolih has extensive experience in manag... 
 Printer Friendly Version
5/22/2001Meridian Bioscience Reports On Profitable Operations, Increased Production and Plans to Expand Credit Facility
CINCINNATI--(BW HealthWire)--May 22, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced operating results for the month of April were profitable, consistent with the Company's earlier public statements that it expected operating results would become profitable during the current quarter. Quoting from the April 24, 2001, press release, "Notwithstanding the operating losses reported for the second quarter and first half of fiscal 2001, meaningful progress has been made in i... 
 Printer Friendly Version
5/14/2001Meridian Announces Patent Filing Describing the Correlation of Colic and H. pylori Infection in Infants
CINCINNATI--(BW HealthWire)--May 14, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has filed both a U.S. Patent Application and an International Application under the Patent Cooperation Treaty directed to the diagnosis of Helicobacter pylori (H. pylori) associated colic in infants and its treatment with antibiotic and other therapies. H. pylori infection has also been implicated in gastroduodenal diseases such as peptic ulcers, gastritis, and stomach cancer.... 
 Printer Friendly Version
4/24/2001Meridian Reports Second Quarter Results, Declares Regular Cash Dividend and Announces Stock Buyback Program
CINCINNATI, Ohio--(BW HealthWire)--April 24, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO), today reported operating results for the second quarter and six months ended March 31, 2001, declared the regular cash dividend and announced a stock buyback plan, as follows: Second Quarter Operating Results Net sales for the second fiscal quarter ended March 31, 2001, were $13,866,000 as compared to $14,577,000 for the same period of the prior fiscal year, a decrease of ... 
 Printer Friendly Version
4/12/2001Meridian Bioscience Launches Rapid One-Step Test for Direct Detection of Cryptosporidium and Giardia
CINCINNATI--(BW HealthWire)--April 12, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has launched a new rapid, one-step device for the simultaneous detection of two waterborne parasites, Giardia and Cryptosporidium. ImmunoCard STAT!(R) Cryptosporidium/Giardia, gives accurate, easy-to-read results in just minutes. Giardia lamblia and Cryptosporidium are waterborne parasites causing acute diarrhea and gastrointestinal dist... 
 Printer Friendly Version
4/2/2001Meridian Bioscience Hires Vice President of Operations
CINCINNATI--(BUSINESS WIRE)--April 2, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has hired Larry Baldini as its Vice President of Operations. Most recently, Mr. Baldini was Director of Operations (Sensory Systems) at Instrumentation Laboratories, Ann Arbor, MI; he previously held the titles of Operations Manager and Facilities Manager. Mr. Baldini has extensive experience in managing a wide variety of operations, including implementing quality systems (QSRs an... 
 Printer Friendly Version
3/28/2001Meridian Bioscience Announces Important Supply Contract and Comments on Return to Profitable Operations and Capital Adequacy
CINCINNATI--(BW HealthWire)--March 28, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced it has entered into a long-term supply agreement with Zeus Scientific, Inc. for 27 products to be marketed under the Meridian Bioscience brand name. Zeus Scientific, headquartered in Raritan, New Jersey, is a well-established and highly regarded developer and producer of infectious disease serology products. The launch date for the Zeus-manufactured, Meri... 
 Printer Friendly Version
2/9/2001Meridian Announces Fiscal Year 2001 First Quarter Results
CINCINNATI--(BW HealthWire)--Feb. 9, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced net sales for the first fiscal quarter that ended December 31, 2000, of $15,254,000 compared to $14,329,000 for the corresponding period of the prior fiscal year. Meridian reported a net loss of ($8,192,000) or ($0.56) per share for the first quarter of fiscal 2001, reflecting charges for its European restructuring plan ($657,000, after tax) and other charges of ($8,500,000, ... 
 Printer Friendly Version
1/24/2001Meridian Announces Name Change and Declares Dividend for First Quarter
CINCINNATI--(BW HealthWire)--Jan. 24, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that yesterday shareholders formally approved Meridian's name change. Henceforth, the Company will be Meridian Bioscience, Inc. and trade under the symbol VIVO. Meridian's Board of Directors declared a dividend of $0.065 per share to be paid February 8, 2001 to shareholders of record as of February 1, 2001. The regular quarterly cash dividend is at an indicated annual rate o... 
 Printer Friendly Version
1/8/2001Meridian Diagnostics, Inc., dba Meridian Bioscience, Inc. Announces Ticker Symbol Change
CINCINNATI--(BW HealthWire)--Jan. 8, 2001--Meridian Bioscience, Inc. today announced that effective with commencement of trading tomorrow morning, the Nasdaq ticker symbol for its common stock will be VIVO. As mentioned in the Company's annual report to shareholders, Meridian has moved rapidly beyond its original mission as a manufacturer and distributor of high-quality diagnostic test kits. Our strategies have been broadened to encompass participation in the rapidly evol... 
 Printer Friendly Version
11/16/2000Meridian Diagnostics, Inc. Announces Fiscal Year 2000 Operating Results
CINCINNATI--(BW HealthWire)--Nov. 16, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) Meridian Diagnostics, Inc. Reports fiscal year 2000 per share earnings of $0.49 vs. $0.14 Undertakes European restructuring Announces planned name and NASDAQ symbol change to reflect expanding business capabilities Declares regular cash dividend and increases indicated rate for fiscal 2001 O... 
 Printer Friendly Version
11/14/2000Meridian Diagnostics, Inc. Invites You to Participate in its Conference Call to discuss Fiscal Year 2000 Earnings on Thursday, November 16, 2000 at 3:00 p.m. ET
CINCINNATI--(BW HealthWire)--Nov. 14, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) expects to release Fiscal Year 2000 earnings on Thursday, November 16, 2000. There are two alternative communication modes available for you to listen to the call. Option No. 1 ------------ Over the Telephone Call 1-800-491-3423 (domestic) or 303-267-1007 (international), Conference ID 859812. If you plan to participate in the conference call via the telephone, please RSVP to Meridi... 
 Printer Friendly Version
11/1/2000Meridian Diagnostics, Inc. Appoints New Director to its Board
CINCINNATI--(BW HealthWire)--Nov. 1, 2000--Meridian Diagnostics, Inc., (Nasdaq:KITS) today announced that it has appointed David C. Phillips to the Company's Board of Directors, effective immediately. The appointment of Mr. Phillips fills a vacant seat on the Board that has been open since July 1999. Mr. Phillips was with the international accounting firm of Arthur Andersen for 32 years and served in a variety of positions prior to his retirement as firm-wide Managing Part... 
 Printer Friendly Version
10/18/2000Meridian Diagnostics Recognized as One of Forbes 200 Best Small Companies
CINCINNATI--(BW HealthWire)--Oct. 18, 2000--Meridian Diagnostics, Inc., Cincinnati, Ohio (Nasdaq:KITS) today announced that it has been recognized as one of the "Forbes 200 Best Small Companies" as reported in the October 17, 2000 issue of Forbes magazine. The Forbes 200 Best Small Companies list is selected following a comprehensive evaluation of financial results plus additional operating factors of candidate companies having sales between $5 million and $350 million. A... 
 Printer Friendly Version
9/27/2000Meridian Diagnostics Expands Research Partnership with Texas Tech University and Completes Acquisition of Viral Antigens
CINCINNATI, Sept. 27 /PRNewswire/ -- Meridian Diagnostics, Inc. (Nasdaq: KITS) today announced that it has entered into an expanded research agreement with Texas Tech University Health Sciences Center (Lubbock, TX) and Dr. K. John Morrow, Jr. for the development of highly specific, gene-mediated antigen and antibody systems. This project is expected to yield more specific and sensitive biologicals for use in diagnosing and treating disease. Morrow and his Texas Tech collaborato... 
 Printer Friendly Version
9/14/2000Meridian Signs Agreement to Acquire Viral Antigens, Inc.
CINCINNATI--(BW HealthWire)--Sept. 14, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) Leading producer of highly specialized biologicals Expands Meridian's biotechnology capabilities Technology rich, strong proprietary know-how Highly profitable, sound balance sheet Accretive earnings expected Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced it has executed de... 
 Printer Friendly Version
8/30/2000Meridian Signs Major Agreement for Advanced Technology Development
CINCINNATI--(BW HealthWire)--Aug. 30, 2000--Meridian Diagnostics, Inc. (NASDAQ:KITS) today announced that it has entered into exclusive long-term Research, Development and Supply Agreements with STC Technologies, Inc. Bethlehem, PA for a highly sensitive proprietary multi-test diagnostic system. The scope of these agreements includes the development, manufacturing, and sale of a broad range of rapid tests for the detection of infectious diseases including, but not limited to, parasi... 
 Printer Friendly Version
8/28/2000Meridian Announces Major Expansion of Its Biotechnology Resources
CINCINNATI--(BW HealthWire)--Aug. 28, 2000-- Leveraging of Meridian's antibody capabilities Collaboration with university, biotech, and pharmaceutical partners Use of genomic and proteomic science Novel drug and vaccine discovery support, and related diagnostic assays Meridian Diagnostics, Inc., (NASDAQ: KITS) today announced an expansion of its capabilities in biotechnology, research reagent developme... 
 Printer Friendly Version
7/21/2000Meridian Diagnostics Announces Record Third Quarter and Nine Months Operating Results and Declares Regular Cash Dividend
CINCINNATI--(BW HealthWire)--July 21, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) After restating 1999 for a nonmaterial bookkeeping error: Third quarter sales, excluding the impact of currency, increased 9% Third quarter net earnings increased 72% Third quarter EBITDA increased 40% Net income for the first 9 months increased 79% EBITDA for the first 9 months increased 41% Gull Salt Lake City facility sold Meridi... 
 Printer Friendly Version
4/20/2000Meridian Diagnostics Announces Record Earnings
Second quarter net earnings increased 47% Second quarter EBITDA increased 28% Net income for the first 6 months increased 84% EBITDA for the first 6 months increased 44% CINCINNATI--(BW HealthWire)--April 20, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced that net earnings for the second quarter of this fiscal year were a record $1,849,000, or $0.13 per share, compared to $1,256,... 
 Printer Friendly Version
4/6/2000New Study Reports Genital Herpes Can Be Spread By Asymptomatic Individuals
CINCINNATI--(BW HealthWire)--April 6, 2000--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced a recently published study has determined that individuals infected with genital herpes, usually HSV Type 2, can spread the virus to others even when symptoms are not present. This research, published in the New England Journal of Medicine and conducted by Dr. Anna Wald, medical director of the University of Washington's Virology Research Clinic, indicated that infected ... 
 Printer Friendly Version
3/21/2000Meridian Diagnostics Acquires Technology & Marketing Rights From La Jolla Diagnostics for Rapid Tuberculosis -- TB -- Test
CINCINNATI--(BW HealthWire)--March 21, 2000--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) and La Jolla Diagnostics (LAJD) today announced an agreement for an undisclosed cash payment and future royalties for a unique rapid blood test for active tuberculosis from the DiagnosTech subsidiary of La Jolla Diagnostics, Inc. The test utilizes a combination of three highly specialized Mycobacterium tuberculosis antigens that will react with blood serum from persons having active TB... 
 Printer Friendly Version
2/22/2000Meridian Receives FDA Clearance To Market Premier C. difficile Toxins A&B
CINCINNATI--(BW HealthWire)--Feb. 22, 2000--Meridian Diagnostics, Inc., (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market Premier™ C. difficile Toxins A&B, the sixth member of the company's C. difficile product family. Toxigenic C. difficile is the major cause of Antibiotic Associated Diarrhea (AAD) and Antibiotic Associated Pseudo-membranous Colitis (PMC), two serious conditions that can ... 
 Printer Friendly Version
1/21/2000Meridian's Board of Directors Declares Dividend for First Quarter Operating Results
CINCINNATI--(BW HealthWire)--Jan. 21, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced that the Board of Directors declared a dividend of $0.06 per share to be paid February 8, 2000 to shareholders of record as of February 1, 2000. The regular quarterly cash dividend is at an indicated annual rate of $0.24 per share, an increase of 20% over the prior year's annual rates. Yesterday, Meridian announced record first quarter operating results with net sales increasi... 
 Printer Friendly Version
1/20/2000Meridian Announces Record First Quarter Operating Results
CINCINNATI--(BW HealthWire)--Jan. 20, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) Net sales increased 22% Net earnings increased 165% EBITDA increased 44% Record fiscal year expected Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales for the first fiscal quarter, which ended December 31, 1999, of $14,329,000 compared to $11,720,000 for the same period of the prior fiscal year. Net earnings for the firs... 
 Printer Friendly Version
11/17/1999Meridian Diagnostics Reports Year-End Operating Results and Increases Dividend Rate
CINCINNATI--(BW HealthWire)--Nov. 17, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) Net sales increased 64% Per share earnings of $0.42 before non-recurring merger integration and purchased research and development costs EBITDA of $12.3 million Annual cash dividend rate increased 20% to $0.24 per share based on strong business outlook for and expectation of record net income for fiscal 2000 Meridian Diagnostics, Inc. (Nasdaq:KIT... 
 Printer Friendly Version
10/22/1999HCFA Announces Coverage of Meridian Diagnostics New Ulcer Test
CINCINNATI--(BW HealthWire)--Oct. 22, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today reported that the United States Health Care Financing Administration (HCFA) has announced their national coverage policy decision relating to Meridian Diagnostics' new non-invasive ulcer test, Premier Platinum HpSA(TM)(HpSA). The purpose of the HpSA test, which was cleared by the Food and Drug Administration (FDA) to market in May 1998, is to aid in the diagnosis of H... 
 Printer Friendly Version
9/28/1999Meridian's Stomach Ulcer Test Unaffected by Common Medications
CINCINNATI--(BW HealthWire)--Sept. 28, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq: KITS) today announced that The American Journal of Gastroenterology (AJG) published an article entitled, ''Effects of Acid Suppression and Bismuth Medications on the Performance of Diagnostic Tests for Helicobacter pylori Infection,'' (Luis E. Bravo, M.D., et. al.). This article reports on a study designed to investigate whether acid suppression and bismuth medications interfere with the... 
 Printer Friendly Version
8/11/1999Meridian's New Rapid Test for E. coli Infections Receives FDA Clearance to Market
CINCINNATI--(BW HealthWire)--Aug. 11, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market ImmunoCard STAT!(TM) E. coli O157 Plus. This rapid test will detect the most prevalent toxigenic strain of E. coli, E. coli O157:H7, which is often transmitted via ground beef, vegetables and other foods. E. coli O157 infects up to 1 million individuals each year in the U... 
 Printer Friendly Version
7/22/1999Meridian Diagnostics Announces Third Quarter and Nine Months Operating Results, Reports Operations At Gull Laboratories Continue to Exceed Expectations, Declares Dividend
CINCINNATI--(BW HealthWire)--July 22, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales of $13,825,000 for the third fiscal quarter ended June 30, 1999, compared to net sales of $8,226,000 for the same period of the prior fiscal year, an increase of $5,599,000, or 68%. Net earnings, excluding the after-tax impact of merger integration costs of $339,000 ($0.03 per share) in connection with the recent acquisition of Gull Laboratories, were $1,684,000 or $0.12 per shar... 
 Printer Friendly Version
7/14/1999Meridian Test Aids in Diagnosis of Toxic E. coli Outbreak
CINCINNATI--(BW HealthWire)--July 14, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that its Premier EHEC test was used to diagnose young adults impacted by an outbreak of toxigenic E. coli in the state of Texas. It has been determined that the bacteria Escherichia coli (E. coli) strain O111 was the cause of illness in more than 52 individuals. Specimens were tested for E. coli O157:H7, the more commonly-known form of E. coli, but produced a negative... 
 Printer Friendly Version
7/12/1999Meridian Type-Specific Herpes Tests Receive FDA Clearance to Market
CINCINNATI--(BW HealthWire)--July 12, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market two diagnostic tests for the herpes simplex virus. These tests, Premier(TM) Type-Specific HSV-1 IgG ELISA Test and Premier(TM) Type-Specific HSV-2 IgG ELISA Test, are the first medical tests cleared by the FDA that have been proven to be able to distinguish Herpes Simplex... 
 Printer Friendly Version
7/7/1999The Lancet Publishes Article on Meridian's HpSA Test for Stomach Ulcers
CINCINNATI--(BW HealthWire)--July 7, 1999--Meridian Diagnostics, Inc., (Meridian) (Nasdaq:KITS) today announced that the esteemed medical journal, The Lancet, published an article entitled, "Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay," (Dr. D. Vaira, et. al.). This article reports on a study designed to confirm the accuracy of Meridian's Premier Platinum HpSA(TM) (HPSA), the newly developed test for the detection of the H. pylori antigen which ... 
 Printer Friendly Version
6/29/1999William J. Motto, CEO Of Meridian Diagnostics, Receives 1999 Entrepreneur of the Year Award
    Business Editors, Health & Medical Writers     CINCINNATI--(BW HealthWire)--June 29, 1999--Meridian Diagnostics, Inc., (Nasdaq:KITS), today announced that William J. Motto, Chief Executive Officer, received The Cincinnati/Northern Kentucky 1999 Ernst & Young Entrepreneur of the Year Award in the Technology division. This prestigious Award, given annually to owners and managers, honors the area's entrepreneurs consisting of 26 total finalists. ... 
 Printer Friendly Version
4/21/1999Meridian Diagnostics Announces Second Quarter and First Half Operating Results, Reports Profitable Operations At Gull Laboratories, and Declares Regular Cash Dividend
    Business Editors, Health/Medical Writers     CINCINNATI--(BW HealthWire)--April 21, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales of $14,654,000 for the second quarter of fiscal 1999 ended March 31, 1999, compared to net sales of $9,542,000 for the same period of the prior fiscal year, an increase of $5,112,000, or 54%. Net earnings, excluding the after-tax impact of merger integration costs of $425,000 ($0.03 per ... 
 Printer Friendly Version
1/28/1999Meridian Announces Operating Results Including Record Sales for the First Quarter of Fiscal 1999
CINCINNATI--(BW HealthWire)--Jan. 28, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net sales for the first fiscal quarter ended December 31, 1998 of $11,720,000, compared to net sales of $8,448,000, during the same period of the prior fiscal year. Net earnings, excluding the after-tax impact of one-time restructuring and integration costs of $280,000 ($0.02 per share) associated with the acquisition of Gull Laboratories on November 5, 1998, were $834,000 ($0.06 per share... 
 Printer Friendly Version
12/29/1998Quest Diagnostics Now Offers Meridian's New Premier Platinum HpSA -- Stomach Ulcer -- Test
CINCINNATI--(BW HealthWire)--Dec. 29, 1998--Meridian Diagnostics, Inc., (Nasdaq:KITS) announced today that its Premier Platinum HpSA (TM) stomach ulcer test is now available through Quest Diagnostics Incorporated and its network of laboratories. HpSA (Helicobacter pylori Stool Antigen), cleared for marketing by the United States Food and Drug Administration (FDA) in May 1998, is the first noninvasive direct test for H. pylori, the bacteria that causes most stomach ulcers. A more recent ... 
 Printer Friendly Version
12/22/1998New Claims for Meridian Stomach Ulcer Test Cleared By FDA
CINCINNATI--(BW HealthWire)--Dec. 22, 1998--Meridian Diagnostics, Inc., (Nasdaq:KITS) announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market Premier Platinum HpSA(TM) (Helicobacter pylori Stool Antigen) to monitor therapeutic response in patients with H. pylori infection. Premier Platinum HpSA was initially cleared for marketing in May 1998 for diagnosis of H. pylori infection. H. pylori is the bacteria that causes most stomach ... 
 Printer Friendly Version
11/20/1998Meridian Diagnostics, Inc. Declares Regular Quarterly Dividend and Comments on Dividend Policy
CINCINNATI--(BW HealthWire)--Nov. 20, 1998--The Board of Directors of Meridian Diagnostics, Inc. (Nasdaq: KITS) announced declaration of the resulting quarterly cash dividend of $0.05 per share to be paid December 8, 1998 to shareholders of record on November 25, 1998. The cash dividends paid and to be paid with regard to the Company's fiscal 1998 operating results total approximately $2,876,000 which represents a dividend payout ratio of 58%. Based on the Company's fiscal 1998 ... 
 Printer Friendly Version
11/13/1998Meridian Diagnostics Announces Fourth Quarter and Fiscal Year-end Results
CINCINNATI--(BW HealthWire)--Nov. 13, 1998--Meridian Diagnostics, Inc. (Nasdaq: KITS) , Cincinnati, Ohio, today announced net sales and net earnings for the fourth fiscal quarter ended September 30, 1998 of $6,952,000 and $853,000 ($.06 per share), respectively, as compared to net sales and net earnings of $10,248,000 and $2,310,000 ($.16 per share), respectively, during the same period of the prior fiscal year. Net sales and net earnings for the fiscal year ended September 30, 1998 ... 
 Printer Friendly Version
11/6/1998Meridian Diagnostics Completes Acquisition of Gull Laboratories and Implements Cost-Cutting Plans
CINCINNATI--(BW HealthWire)--Nov. 6, 1998--Meridian Diagnostics, Inc., (Nasdaq: KITS) today announced the completion of the Gull Laboratories, Inc. (AMEX: GUL) acquisition. Gull common stock ceased trading at the close of business on the American Stock Exchange on November 5, 1998. The transaction was approved by a special meeting of the shareholders of Gull Laboratories, held November 5, 1998. The former shareholders of Gull Laboratories will receive $2.25 in cash for each common sh... 
 Printer Friendly Version
10/2/1998Meridian Diagnostics Announces Preliminary Fourth Quarter Results
CINCINNATI--(BW HealthWire)--Oct. 2, 1998--Meridian Diagnostics, Inc., (Nasdaq: KITS) today announced, based on a preliminary review of its operating results for the fourth quarter ended September 30, 1998, that it expects net sales of approximately $7.0 million, down approximately $3.0 million, over the same period of the prior fiscal year. Net earnings are estimated to be in the range of $0.7 million to $1.0 million as compared to $2.3 million for the fourth quarter of fiscal 1997. Dilu... 
 Printer Friendly Version
9/16/1998Meridian Diagnostics and Gull Laboratories Execute Definitive Agreement to Merge
CINCINNATI--(BW HealthWire)--Sept. 16, 1998--Meridian Diagnostics, Inc., (NASDAQ: KITS) today announced that it has entered into a definitive agreement to acquire Gull Laboratories, Inc. (ASE: GUL) through a merger transaction. The shareholders of Gull Laboratories will receive $2.25 in cash for each common share. Fresenius AG, the majority shareholder of Gull Laboratories, has agreed, subject to certain conditions, to vote its Gull shares in favor of the merger. The transaction is ... 
 Printer Friendly Version